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ABSTRACT
The pentose phosphate pathway (PPP) is a fundamental component of cellular metabolism. The PPP is
important to maintain carbon homoeostasis, to provide precursors for nucleotide and amino acid biosynthesis,
to provide reducing molecules for anabolism, and to defeat oxidative stress. The PPP shares reactions with
the Entner–Doudoroff pathway and Calvin cycle and divides into an oxidative and non-oxidative branch.
The oxidative branch is highly active in most eukaryotes and converts glucose 6-phosphate into carbon
dioxide, ribulose 5-phosphate and NADPH. The latter function is critical to maintain redox balance under
stress situations, when cells proliferate rapidly, in ageing, and for the ‘Warburg effect’ of cancer cells. The
non-oxidative branch instead is virtually ubiquitous, and metabolizes the glycolytic intermediates fructose
6-phosphate and glyceraldehyde 3-phosphate as well as sedoheptulose sugars, yielding ribose 5-phosphate for
the synthesis of nucleic acids and sugar phosphate precursors for the synthesis of amino acids. Whereas the
oxidative PPP is considered unidirectional, the non-oxidative branch can supply glycolysis with intermediates
derived from ribose 5-phosphate and vice versa, depending on the biochemical demand. These functions
require dynamic regulation of the PPP pathway that is achieved through hierarchical interactions between
transcriptome, proteome and metabolome. Consequently, the biochemistry and regulation of this pathway,
while still unresolved in many cases, are archetypal for the dynamics of the metabolic network of the cell. In
this comprehensive article we review seminal work that led to the discovery and description of the pathway that
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date back now for 80 years, and address recent results about genetic and metabolic mechanisms that regulate
its activity. These biochemical principles are discussed in the context of PPP deficiencies causing metabolic
disease and the role of this pathway in biotechnology, bacterial and parasite infections, neurons, stem cell
potency and cancer metabolism.
Key words: pentose phosphate pathway, glycolysis, glucose 6-phosphate dehydrogenase, NADPH,
metabolomics, oxidative stress, cancer, stem cells, host–pathogen interactions, metabolic engineering,
inherited metabolic disease, parasitic protozoa, metabolism of infection.
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I. INTRODUCTION
Next to glycolysis (Embden–Meyerhof–Parnas path-
way) and the tricarboxylic acid (Krebs) cycle, the pen-
tose phosphate pathway (PPP) was one of the first
metabolic pathways to be discovered. Work on the PPP
was stimulated by the famous Otto Warburg labora-
tory in Berlin-Dahlem. In the 1930s Warburg demon-
strated that the pyridine nucleotide diphosphopyridine
nucleotide DPN (now known as NAD+) functions as
an electron carrier (Warburg, Christian & Griese, 1935;
Warburg & Christian, 1936). In addition, this work
revealed the existence of a second coenzyme, termed
triphosphopyridine nucleotide TPN (now widely known
as NADP+), that is required for the oxidation of glu-
cose 6-phosphate to 6-phosphogluconate, by an enzyme
which was purified from yeast and erythrocytes and
named Zwischenferment [‘intermediate enzyme’ now glu-
cose 6-phosphate dehydrogenase (G6PDH)] (Warburg
et al., 1935; Warburg & Christian, 1936; Dickens, 1938).
The TPN dependence of the Zwischenferment led to
the speculation that there might be a pathway parallel
to glycolysis, involved in the direct oxidation of glucose
(reviewed by (Horecker, 2002)).Work in the subsequent
three decades, driven substantially by BernardHorecker
at Cornell University, but with important contributions
by other leading biochemists including Arthur Korn-
berg, TerryWood, FrankDickens, Fritz Lipmann, Severo
Ochoa, Hans Klenow and others, yielded a draft ver-
sion of the pathway that was presented in 1955 (Gun-
salus, Horecker & Wood, 1955). However, it took fur-
ther decades to complete the canonical pathway map as
we know it today, with some enzymes being added only
recently [i.e. sedoheptulokinase (SHPK) in humans
(Wamelink et al., 2008b) and sedoheptulose 1,7 bispho-
sphatase (SH17BPase) in yeast (Clasquin et al., 2011)].
Meanwhile, the PPP has gained recognition as being a
central player in cellular biosyntheticmetabolism and in
controlling and maintaining the redox homeostasis of
cells. As such, it has been implicated in several human
diseases including metabolic syndrome, neurodegen-
eration (Alzheimer’s disease), cardiovascular disease,
parasite infections and cancer (Wood, 1985; Zimmer,
1992; Zimmer, 2001; Schaaff-Gerstenschlager & Zim-
mermann, 1993; Gupte, 2008; Mayr et al., 2008; Orešicˇ
et al., 2011; Vander Heiden et al., 2011; Riganti et al.,
2012; Wallace, 2012).
II. BIOCHEMISTRY AND EVOLUTIONARY
ORIGIN OF THE PENTOSE PHOSPHATE
PATHWAY
The biochemical reactions that constitute the PPP
are, evolutionarily speaking, very old, and seem to
accompany life since the earliest steps of evolution.
Indeed, metal-catalysed enzyme-free reactions analo-
gous to the PPP are observed in a reconstructed
reaction milieu of the prebiotic Archean ocean. This
indicates that the basic structure of the PPP is of
pre-enzymatic origin and may descend from chemically
constraint pre-biotic metal-catalysed sugar phosphate
interconversions (Keller, Turchyn & Ralser, 2014). The
modern cellular PPP however is catalysed by sophis-
ticated enzymes, except one step, the interconversion
of 6-phosphoglucono-𝛿-lactone to 6-phosphogluconate,
which is still considered at least partly spontaneous
(Wood, 1985; Horecker, 2002). These enzymatic reac-
tions subdivide the PPP into two biochemical branches,
known as the oxidative and non-oxidative PPP (see Fig. 1
for an overview of the pathway, and Table 1 for its
enzymes).
Reactions of the non-oxidative PPP (with the over-
lapping Calvin cycle and Entner–Doudoroff pathways),
occur virtually ubiquitously, and maintain a central
metabolic role in providing the RNA backbone pre-
cursors ribose 5-phosphate and erythrose 4-phosphate
as precursors for aromatic amino acids. By contrast,
the oxidative branch of the PPP is not universal and
is absent in many aerobic and thermophilic organ-
isms (Grochowski, Xu & White, 2005; Nunoura et al.,
2011; Bräsen et al., 2014). While reactions of the
non-oxidative branch can also occur non-enzymatically,
reactions concerning the interconversion of glucose
6-phosphate to 6-phosphogluconate, defining the
oxidative PPP, were not observed in the Archean
ocean simulations (Keller et al., 2014). This obser-
vation might indicate that the oxidative part of
the PPP pathway is evolutionarily newer than the
non-oxidative branch. Nonetheless, in the majority
of eukaryotes the oxidative branch is highly active
and converts the glycolytic/gluconeogenetic metabo-
lite glucose 6-phosphate into ribulose 5-phosphate
via the consecutive reactions of G6PDH [in yeast
still named Zwf1 (ZWischenFerment) in acknowl-
edgement of Otto Warburg’s original nomenclature],
6-phosphogluconolactonase (6PGL) [catalysing a
reaction which can also occur spontaneously but the
enzyme increases its specificity (Miclet et al., 2001)]
Biological Reviews (2014) 000–000 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
4 A. Stincone and others
Fig. 1. Schematic representation of the pentose phosphate pathway (PPP, left) and glycolysis (canonical topology of the
Embden-Meyerhof-Parnas pathway) (right). The enzymatic reactions constituting both pathways are represented by double
or single arrows, according to the reversibility of the reactions. The oxidative and non-oxidative branches of the PPP are
highlighted by background coloring. Sedoheptulose conversion enzymes found in *bacteria; **fungi (S. cerevisiae) and
plants, ***mammals. Abbreviations are defined in Table 1; FBA, fructose bisphosphate aldolase; HK, hexokinase; PFK,
phosphofructokinase; PK, pyruvate kinase; SH17BP, SH17BPase.
and 6-phosphogluconate dehydrogenase (6PGDH).
This metabolic sequence yields two NADPH per metab-
olized glucose 6-phosphate. Next, the formed ribulose
5-phosphate enters the non-oxidative branch and
can be converted either to ribose 5-phosphate by ribose
5-phosphate isomerase (RPI) or to xylulose 5-phosphate
by ribulose 5-phosphate epimerase (RPE). While ribose
5-phosphate is required to form the RNA andDNAback-
bone, erythrose 4-phosphate is required as precursor
for the biosynthesis of histidine, for various aromatic
metabolites in aromatic amino acid prototrophic
organisms and it plays a role in vitamin B6 metabolism
(Zimmer, 1992; Wang, Xie & Schultz, 2006; Cadière
et al., 2011; Clasquin et al., 2011; Zhao et al., 1995).
The RPI and RPE reactions set the stage for com-
pleting the pathway though conversion of ribose
5-phosphate and xylulose 5-phosphate and the gly-
colytic/gluconeogenetic intermediates glyceraldehyde
3-phosphate and fructose 6-phosphate via reshuffling
of the monophosphate sugars. These reactions are
catalysed by the two enzymes transketolase (TKL) and
transaldolase (TAL), which are responsible for relatively
complex (multi-substrate) interconversion reactions at
the core of the non-oxidative PPP (Fig. 1).
Biological Reviews (2014) 000–000 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
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TKL uses a ketose donor (xylulose 5-phosphate) and
aldose acceptors (ribose 5-phosphate or erythrose 4-
phosphate) to form aldose and ketose products (glycer-
aldehyde 3-phosphate and sedoheptulose 7-phosphate
or fructose 6-phosphate, respectively), to catalyse the
transfer of two-carbon fragments (‘activated glycolalde-
hyde’) for monosaccharide interconversion (Schenk,
Duggleby &Nixon, 1998). Hence, this enzyme is respon-
sible for two distinct reactions within the non-oxidative
PPP. TKL activity is dependent on the cofactor thiamine
diphosphate (Lindqvist et al., 1992; Schenk et al., 1998;
Kochetov & Sevostyanova, 2005). The cofactor is bound
at the interface between the two subunits of TKL a
homodimer, with two identical catalytic sites (Lindqvist
et al., 1992; Kochetov & Sevostyanova, 2005).
TAL instead catalyses the transfer of the three-carbon
fragment dihydroxyacetone between sugar phosphates
up to eight carbons in length via the formation of a
Schiff base at a lysine residue in the active site (Miosga
et al., 1993; Banki & Perl, 1996; Samland & Sprenger,
2009). Its donor substrates are ketose sugar phosphates
which include fructose 6-phosphate and sedoheptulose
7-phosphate and its acceptor substrates are the aldose
sugar phosphates glyceraldehyde 3-phosphate and ery-
throse 4-phosphate (Samland & Sprenger, 2009).
By sharing these intermediate metabolites with
glycolysis (fructose 6-phosphate and glyceraldehyde
3-phosphate), TAL and TKL act as a bridge between
glycolysis and the PPP. In addition, they connect
to sedoheptulose 7-phosphate which is synthesized
also by other sources. These include the recently
described enzyme sedoheptulokinase [SHPK, also
known under the former systematic name carbohydrate
kinase-like (CARKL)] in mammals (Kardon et al., 2008;
Wamelink et al., 2008b). SHPK catalyses the phosphory-
lation of sedoheptulose to sedoheptulose 7-phosphate
though ATP consumption in a biochemical reaction
first described in 1955 (Ebata, Sato & Bak, 1955).
Other novel enzymes that metabolize sedoheptulose
7-phosphate are sedoheptulose 1,7-bisphosphatase
(SH17BPase) in yeast (Clasquin et al., 2011) and
sedoheptulose 7-phosphate isomerase (SHI) in bac-
teria (Kneidinger et al., 2001; Valvano, Messner &
Kosma, 2002; Taylor et al., 2008). Hence, sedoheptu-
lose 7-phosphate represents a glycolysis-independent
entry and exit point into/from the non-oxidative PPP.
The formation of this metabolite connects the PPP
with open chain and polyol sugar metabolism and
bacterial lipopolysaccharide biosynthesis. These con-
nections with both glycolysis, amino acid biosynthesis
and open-chain sugar metabolism place the PPP central
to the metabolic network. Moreover, its flux and reg-
ulation not only depend on, but also influence its
neighbouring metabolic routes, which might explain in
part the extensive regulation of this biochemical route,
as detailed in later sections of this article.
Analysis in yeast and mammalian cells has shown that
with the exception of RPI, most of the PPP enzymes
are not essential for survival at the cellular level. At
the organism level in mammals, at least partial defi-
ciencies of PPP enzymes G6PDH, 6PGDH, TAL and
RPI are viable as well, but lead to severe genetic dis-
ease (see Section VI). However, no disease pheno-
types or deficiencies have been reported for the other
PPP enzymes; most likely their deficiency is embry-
onically lethal to mammalian organisms, indicating
that the PPP as pathway is essential. Indeed, double
gene deletions that affect both the oxidative and the
non-oxidative PPP are also lethal down to the cellular
level (Schaaff-Gerstenschlager & Zimmermann, 1993;
Juhnke et al., 1996; Krüger et al., 2011). The viability
of the partial PPP deficiencies and several null alleles
therefore indicates that the oxidative and non-oxidative
branches of the PPP can work independently; each of
the two parts can compensate and provide sufficient
sugar phosphate precursors required for cellular sur-
vival.
(1) The L-type PPP and alternative or extended
reaction sequences of the PPP
The PPP might also exist in alternative reaction
sequences. Named the L-type PPP, a reaction sequence
was proposed in liver cells that involves flux over
alternative metabolites such as arabinose 5-phosphate
and glycero-ido-octulose phosphate (Williams et al.,
1984). Also, alternative seven-carbon phosphates and
their diphosphates have been associated with the PPP
(Wood, 1985). (Longenecker & Williams, 1980) sug-
gested that up to 30% of the PPP flux in hepatocytes
could be attributable to these alternative PPP forms.
Nevertheless, there is only limited confirmation of
these PPP alternatives, indeed biochemical evidence
for them has been questioned (Landau & Wood, 1983).
Therefore, these alternatives are not addressed in
detail herein. The recent discovery of the PPP enzymes
SHPK and the SH17BPase however indicates that
the full biochemical spectra of the PPP could exceed
the core reactivity of the canonical pathway (Fig. 1),
and hence that additional discoveries might still be
made.
(2) The subcellular localization of the PPP and its
enzymes
In most organisms, including fungi and metazoa, the
PPP is localized in the cytosol, and contributes both
to the cytoplasmic metabolite as well as redox cofac-
tor pool. However, important exceptions do exist. The
pathway is split between the cytosol and other organelles
such as the plastid, peroxisomes or glycosomes in plants
and parasitic protozoa, respectively (Zimmer, 2001;
Hannaert et al., 2003; Kruger & von Schaewen, 2003).
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Part of the PPP might occur in the endoplasmic retic-
ulum (ER) too. Microsomes, vesicles formed from the
ER when cells are mechanically homogenized, con-
tain at least five PPP enzymes. These include hexose
6-phosphate dehydrogenase (H6PDH), an enzyme
similar to G6PDH (Bublitz & Steavenson, 1988; Nelson,
Lehninger & Cox, 2008; Senesi et al., 2010) that is
required to provide NADPH to the luminal reductases
(Beutler & Morrison, 1967; Takahashi & Hori, 1978;
Senesi et al., 2010). H6PDH has a broader range of
substrates than G6PDH and it was described as being
non-selective regarding the nucleotide cofactor (NAD+
and NADP+). The concentration of reduced NADP(H)
in the endoplasmic lumen suggested that under physio-
logical conditions glucose 6-phosphate and NADP+ are
preferred. Hence, while the PPP is largely a cytosolic
pathway, alternative organelle localisations do exist and
are of significant importance.
(3) Glucose 6-phosphate dehydrogenase (G6PDH)
and the role of the oxidative PPP in NADPH synthesis
The most intensively studied enzyme of the PPP is
G6PDH, an NADP+-dependent oxidoreductase. This
enzyme has often been quoted as being rate limit-
ing for the oxidative branch of the PPP. Although
the classic concept of ‘rate limitation’ has its limita-
tions (Kacser, 1995), the first enzymatic step involving
G6PDH is certainly of central importance as the oxida-
tive PPP is largely considered unidirectional. Eukary-
otic G6PDH was first discovered in different strains of
brewery yeast (Dickens, 1938), and to date this model
organism has served for dissecting most of the func-
tionality of the PPP. Budding yeast G6PDH is encoded
by a single gene YNL241C (Nogae & Johnston, 1990;
Thomas, Cherest & Surdin-Kerjan, 1991). Deletion of
this gene retains viability, but zwf1 cells are unable to syn-
thesize methionine. It is assumed that this methionine
auxotrophy is a consequence of the insufficient produc-
tion of NADPH to sustain methionine biosynthesis, and
requires yeast to assimilate ‘inorganic sulphur’ in order
to form ‘organic sulphur’ (methionine or cysteine)
to grow (Masselot & De Robichon-Szulmajster, 1975;
Nogae & Johnston, 1990; Thomas et al., 1991). This
notion of NADPH shortage in zwf1Δ cells is supported
by the observations that (i) when supplying NADPH
from a different source, i.e. through alcohol dehydro-
genase (Ald6), the methionine prototrophy is restored
(Grabowska & Chelstowska, 2003). Moreover (ii), also
yeast cells deleted for cytoplasmic superoxide dismu-
tase (SOD1) become methionine auxotrophs (Slekar,
Kosman & Culotta, 1996). These results indicate that
G6PDH, and the oxidative PPP in general, play a quan-
titative role in NADP+ to NADPH recycling and redox
balancing.
The importance of the NADPH-producing function of
the PPP has been corroborated in several studies mainly
addressing the antioxidant function of this coenzyme in
yeast and mammalian cells. As NADPH is required as a
redox equivalent in the antioxidant machinery, involv-
ing the thioredoxin/peroxiredoxin and glutathione
systems (Pollak, Dölle & Ziegler, 2007a; Grant, 2008),
yeast andmammalian cells deficient for G6PDHbecome
hypersensitive to several oxidants (Juhnke et al., 1996;
Gorsich et al., 2006; Krüger et al., 2011).
Which proportion of the cytoplasmic NADPH pool is
derived from the PPP? It varies, as the activity of the
oxidative PPP is flexibly regulated, and as discussed in
Section III , is actively increased during stress situations.
A flexible flux of the PPP is supported from studies
of NADPH-consuming enzymes, metabolic flux analysis,
but in particular by investigations on the oxidative stress
response. An illustrative example concerns the yeast
NADPH oxidase YNO1, a recently discovered enzyme
that similar to mammalian NADPH oxidases, oxidizes
NADPH to produce superoxide. When YNO1 is over-
expressed in wild-type cells, superoxide levels increase
10-fold. An increase in superoxide levels is however
no longer observed upon deletion of zwf1, indicating
that the oxidative PPP compensates for the increased
NADPH consumption caused by the YNO1 overexpres-
sion (Rinnerthaler et al., 2012).
Yeast cells deficient in NADPH production due to
zwf1 deletion have an almost normal NADPH/NADP+
ratio when growing exponentially and in glucose media.
Their NADPH/NADP+ ratio however collapses when
exposed to oxidants (Castegna et al., 2011). Thus, the
contribution of the oxidative PPP to the cellularNADPH
pool is dynamic and context dependent, and essen-
tial for most cell types only when the NADPH require-
ment is increased. In Section IV we discuss mecha-
nisms that facilitate a dynamic control of PPP activ-
ity under different physiological conditions, which is
achieved through cooperation of transcriptional reg-
ulation, post-translational modifications, and allosteric
control (feedback and feedforward regulation) of the
involved enzymes.
In mammalian cells, G6PDH was intensively studied
because partial deficiency in this enzyme represents the
most common human enzyme defect, and as described
in Section VI, has severe haematological consequences
(haemolytic anaemia). A full depletion of G6PDH in
mammals and nematodes is however lethal at the organ-
ism level (embryonic lethality) (Longo et al., 2002; Ying,
2007) while the same mutation is tolerated at the cel-
lular level (Pandolfi et al., 1995). Similar to yeast cells,
mouse embryonic stem cells possessing a mutation lead-
ing to a strong reduction in G6PDH activity are able
to grow but are sensitive to externally applied oxida-
tive stress (Pandolfi et al., 1995; Filosa et al., 2003). Also,
mouse fibroblasts carrying a permanent deletion of the
G6PDH exon are viable, despite their low clonogenicity
(Filosa et al., 2003).
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(a) Non-PPP sources of NADP(H)
The role of the PPP in providing NADPH has to be seen
in the context of other NADPH oxidoreductases, cellu-
lar compartmentalisation and the NAD(H)/NADP(H)
de novo synthesis pathways. In many cell types and most
conditions, NADP(H) is present mostly in its reduced
form (Ying, 2007; Pollak et al., 2007a). However, this
assumption has a degree of uncertainty.
As membranes are considered to be NADPH
impermeable, the NADPH recycling process and
de novo biosynthesis is compartment-specific (Ying,
2007; Pollak, Niere & Ziegler, 2007b). Hence, in
most organisms the PPP contributes mainly to the
cytoplasmic NADPH pool. In mammalian mature
erythrocytes which have no nucleus and no mito-
chondria, the PPP is generally assumed to be the
dominating source of this coenzyme. In other cell types,
there are important additional cytoplasmic enzymes
that contribute to the NADPH pool, including the
cytosolic isoforms of isocitrate dehydrogenase, glu-
tamate dehydrogenase, methylene-tetrahydrofolate
dehydrogenase, formyl-tetrahydrofolate dehydroge-
nase, aldehyde dehydrogenase and malic enzyme
(Bernt & Bergmeyer, 1974; Wermuth, Münch & von
Wartburg, 1977; Scheibe, 1987; Lee et al., 2002; Fan
et al., 2014). Another source influencing the NADPH
level in mammalian cells, for instance in mitochondria,
appears to be trans-hydrogenation between NADH and
NADP+, forming NAD+ and NADPH (Jackson, 2003;
Venditti, Napolitano & Di Meo, 2013). The enzyme
catalysing this reaction, nicotinamide nucleotide
trans-hydrogenase, is an energy-driven integral protein
of the inner mitochondrial membrane, and required in
mitochondria to maintain their high NADPH/NADP+
ratio (Ronchi et al., 2013).
Finally, in the debate about NADPH sources its de novo
synthesis is less often taken into account. The synthesis
of NADPH de novo is achieved by phosphorylation of
NAD(H) by NAD kinase enzymes (Bieganowski et al.,
2006; Pollak et al., 2007a). The lack of an NADP(H)
phosphatase in many organisms implies that the de novo
synthesis might primarily be used for the initial synthe-
sis of the NADP(H) molecules, and not necessarily for
controlling the NADP+/NADPH balance. Nonetheless
it remains plausible that certain cells might be able to
compensate for a lack of NADPH by de novo synthesis of
the reduced form by phosphorylation of NADH.
(b) The synthesis of ribulose 5-phosphate in the non-oxidative
PPP
The pentose phosphate pathway in yeast and mammals
shares much with the most important carbon assimi-
latory pathway in plants, the Calvin cycle. Reverse flux
through the complete PPP could in theory assimilate
carbon in a cyclic manner. The problem is that certain
reactions of the oxidative PPP are not readily reversible.
Accordingly, the Calvin cycle bypasses these reactions
via ribulose 1,5-bisphosphate carboxylase oxygenase
(Rubisco), apparently the most abundant metabolic
enzyme in the biosphere (Raines, 2003). Rubisco con-
verts ribulose 1,5-bisphosphate plus carbon dioxide
into two molecules of 3-phosphoglycerate. While this
enzyme is not shared with the PPP, other Calvin cycle
reactions are (Fig. 2).
In particular, both the non-oxidative PPP and the
Calvin cycle interconvert a total of 15 pentose car-
bon atoms (contained in ribulose 5-phosphate) with
15 glycolytic carbon atoms (in the form of fructose
6-phosphate and glyceraldehyde 3-phosphate), shar-
ing some important reactions. However, while the
classical non-oxidative PPP uses TAL to make sedohep-
tulose 7-phosphate, the Calvin cycle uses the glycolytic
enzyme fructose-bisphosphate aldolase (FBA) to con-
vert erythrose 4-phosphate plus dihydroxyacetone
phosphate into sedoheptulose 1,7-bisphosphate, which
in turn is hydrolysed by the enzyme SH17BPase to
yield sedoheptulose 7-phosphate. This hydrolysis step
provides the thermodynamic driving force, pushing the
Calvin cycle towards ribulose 5-phosphate. Thus, while
the non-oxidative PPP is reversible, the Calvin cycle
is not.
Because FBA is a ubiquitous enzyme (playing an
essential role in glycolysis and gluconeogenesis, and
also producing sedoheptulose 1,7-bisphosphate), the
distinguishing enzyme of the Calvin cycle’s path from
triose phosphates to pentose phosphates is SH17BPase.
Until recently, this enzymatic activity was thought to
be specific to photosynthetic organisms. Metabolomic
screening of yeast strains lacking genes of unknown
function, however, revealed a strain with elevated
sedoheptulose 1,7-bisphosphate. The associated gene
was subsequently shown to encode an enzyme with
SH17BPase activity involved in a novel variant of
the non-oxidative PPP that follows yet more closely
the Calvin cycle reaction sequences (Clasquin et al.,
2011). This thermodynamically driven variant of the
non-oxidative PPP is termed riboneogenesis. Just as
gluconeogenesis uses the energy of a sugar phosphate
bond to convert trioses into hexoses, riboneogenesis
uses one to drive flux from trioses to pentoses.
Ribose 5-phosphate biosynthesis via riboneogenesis
is useful when demand for ribose exceeds that for
NADPH. In such cases it is presumably advantageous to
have a thermodynamically driven alternative to the stan-
dard non-oxidative PPP, and to avoid an over-reduction
of the NADPH pool. Evidence for this effect was
provided by experiments in yeast (Clasquin et al.,
2011). The cells were fed with glucose labelled selec-
tively at the 6-position with carbon 13 (6-13C-glucose).
Such glucose produces doubly labelled sedoheptulose
7-phosphate selectively via SH17BPase. This labelling
pattern was observed preferentially when yeast cells
were grown on media that decreased their need for
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Fig. 2. The light-independent reactions of carbon fixation in the Calvin cycle share enzymes and reactions with the
pentose phosphate pathway (PPP) and glycolysis. Abbreviations are defined in Table 1; PGK, phosphoglycerate kinase;
PRK, phosphoribulokinase, TK, transketolase; FBA, fructose-bisphosphate aldolase.
NADPH (e.g. by providing them with lipids). One can
envision the possibility that growing mammalian cells,
including cancer cells, could also in some circumstances
need ribose 5-phosphate in excess of NADPH, i.e. when
DNA and RNA nucleotide synthesis is maximized (Fer-
reira, 2010; Cairns et al., 2011). So far, however, has
not been observed in doubly labelled sedoheptulose
7-phosphate 6-13C-glucose in mammalian cells (J. D.
Rabinowitz, unpublished results). Thus, SH17BPase
activity plays a role in plant and microbial metabolism,
but not necessarily in animals.
In mammalian cells, a different additional influx
into the sedoheptulose 7-phosphate PPP has been dis-
covered recently: SHPK. This enzyme was identified
based on the observation that several patients suf-
fering from nephropathic cystinosis (CTNS) possess
elevated urinary concentrations of sedoheptulose. In
these patients, the CTNS gene was lost due to a 57 kb
deletion, which aside from the CTNS gene also con-
tained a gene encoding for a carbohydrate kinase-like
(CARKL) protein. Biochemical assays have then shown
that CARKL is in fact a sedoheptulokinase (SHPK)
and catalyses the ATP-dependent phosphorylation of
sedoheptulose (Kardon et al., 2008; Wamelink et al.,
2008b). Apparently, the existence of SHPK implies
that mammalian cells are able to convert sedoheptu-
lose, and thus non-phosphorylated sugars, into ribose
5-phosphate and glycolytic intermediates. The role of
SHPK could be to prevent an accumulation of sedo-
heptulose and related sugars in the clearance of polyol
metabolites (Kardon et al., 2008; Wamelink, Struys &
Jakobs, 2008a). Moreover, expressing this gene in yeast
increased H2O2-resistance, indicating that a second bio-
logical role of SHPK could consist of providing an
increase of the PPP flux during the oxidative stress
(Krüger et al., 2011). Finally, as discussed in Section
VII, SHPK could also ‘report’ altered metabolism to
the immune system; expression of this gene directs
macrophage polarization through control of glucose
metabolism (Haschemi et al., 2012).
III. THE GLYCOLYSIS/PPP TRANSITION:
METABOLIC AND TRANSCRIPTIONAL
MECHANISMS THAT CHANGE PPP FLUX UPON
DEMAND
The survival of a cell in its ever-changing environ-
ment depends on the robustness, interconnection and
functionality of its biological networks. These are highly
dynamic and respond to changing endogenous and
exogenous conditions by interactions of a specific and
limited set of components (Ihmels, Levy & Barkai,
2004; Ralser et al., 2007; Chechik et al., 2008; Buescher
et al., 2010; Fendt et al., 2010; Grüning, Lehrach &
Ralser, 2010). Such dynamic activity is particularly rel-
evant for the metabolic network, where a few hundred
metabolites are interconnected through biochemical
reactions within metabolic modules, providing energy
and biomolecules depending on substrate availabilities,
enzyme activities and cellular demands. Therefore, to
ensure proper functionality of the metabolic network
upon environmental changes, metabolism is adapted.
These adaptations involve the production of increased
amounts of components needed and decreased concen-
trations of those unneeded, to save resources and energy
simultaneously, and importantly, maintain homeostasis
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and prevent a collapse of the metabolic network. More-
over, these reconfigurations are highly regulated ensur-
ing that concentrations of general cofactor metabolites,
such as NAD(H), NADP(H) and A(T)P are not falling
to fatal levels, the flux of the metabolic network is
stabilized, and enzyme activity and abundance of the
metabolicmodule is adjusted (Ihmels et al., 2004; Patil &
Nielsen, 2005; Cakir et al., 2006; Ralser et al., 2009; Grün-
ing et al., 2010; Heinemann & Sauer, 2010).
(1) Regulation of the PPP during the oxidative stress
response
A paradigm example to study the rapid metabolic as
well as transcriptional regulation of the metabolic net-
work is the response of the PPP to oxidative stress. As
aforementioned, in yeast the NADPH-producing role
of G6PDH is compensated by other NADP-oxidizing
enzymes under normal growth conditions. However
the NADP+/NADPH ratio collapses upon a hydrogen
peroxide (H2O2) exposure, rendering G6PDH null
cells highly oxidant sensitive (Nogae & Johnston, 1990;
Todisco et al., 2006; Castegna et al., 2010). Indeed, the
activity of the PPP is rapidly augmented when cells are
exposed to the oxidant. To induce this metabolic transi-
tion, metabolic and gene regulatory mechanisms coop-
erate (Fig. 3). In the first seconds upon an oxidative
burst, enzymes of glycolysis, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Ralser et al., 2007) and pyru-
vate kinase (PK) (Anastasiou et al., 2011; Grüning et al.,
2011) are inactivated causing a block in glycolysis,
while the flux of the PPP continues (Shenton & Grant,
2003; Ralser et al., 2007; Ralser et al., 2009). This rapid
response lasts a few seconds to minutes, then tran-
scriptional responses take over and maintain higher
PPP activity through up-regulation of enzymes and
post-translational modifications, including those which
increase the activity of G6PDH (Chechik et al., 2008;
Ralser et al., 2009; Cosentino, Grieco & Costanzo, 2011;
Wang et al., 2014). This tight regulation seems to have
a dual role. During normal growth, it prevents an over-
production of NADPH and PPP intermediates, andmin-
imizes carbon depletion due to CO2 production. At the
same time, it facilitates a rapid cellular response when
stress conditions apply (Shenton & Grant, 2003; Ralser
et al., 2007; Ralser et al., 2009; Grant, 2008).
The temporal inhibition of glycolysis to the benefit
of the PPP flux appears to be dependent on different
mechanisms. GAPDH for instance is rapidly inactivated
by chemical oxidation which correlates well with a boost
in PPP metabolite concentrations observed within a
few seconds (Ralser et al., 2007; Ralser et al., 2009).
Other mechanisms that support the inhibition of gly-
colytic enzymes concerns allosteric control. A higher
activity of the PPP is maintained by feedback inhibition
of triosephosphate isomerase (TPI) by the glycolytic
intermediate phosphoenolpyruvate (PEP) (Grüning
et al., 2014). PEP is the substrate of pyruvate kinase, that
Fig. 3. Induction of the glycolysis/pentose phosphate
pathway (PPP) transition during oxidative stress. The PPP
plays a pivotal role in counteracting oxidative stress and
is implicated in (i) maintaining metabolic and redox
homeostasis via NADP+ to NADPH reduction, (ii) by syn-
thesizing ribose 5-phosphate used in nucleotide biosyn-
thesis (increased synthesis is required upon DNA dam-
age stress), and (iii) an important role in activating
stress-responsive gene expression. In a stress situation,
activity of the PPP is increased through orchestrated
allosteric/post-translational (=metabolic) and transcrip-
tional regulation, but these are not necessarily acting at
the same time. The fastest response (∼seconds timescale)
is made possible through oxidative inhibition of glycolytic
enzymes represented by the arrow moving from glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) (illus-
trated as a crystallographic structure), which acts as one
of the metabolic switches, while the PPP remains active.
This process is supported by post-translational modifica-
tions that increase glucose 6-phosphate dehydrogenase
(G6PDH) activity. The comparatively slower (=minutes)
process of altering transcript and protein levels allows
for cellular adaptation to stress in the long(er)-term
response. The GAPDH crystallographic structure was
obtained from RCSB-PDB (www.rcsb.org). PDB ID 3PYM:
(DOI:10.2210/pdb3pym/pdb).
itself is controlled allosterically (Lyssiotis et al., 2012;
Morgan et al., 2013). A third strategy that facilitates
rapid PPP activation appear to be post-translational
modifications which affect the activity of G6PDH. In
mammalian and Xenopus laevis cells phosphorylation
and acetylation increase G6PDH activity during the
stress response, so that this enzyme does not become
rate limiting (Cosentino et al., 2011; Wang et al., 2014).
The glycolytic/PPP transition during oxidative stress
is mechanistically related to steady-state adaptation
to physiological conditions that are associated with
increased reactive oxygen species (ROS) production.
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Here, PK and its feedback regulatory function on TPI
and other metabolic enzymes play a crucial regulatory
role. In budding yeast, the activity of PK is reduced when
cells respire at high rate, and less active isoforms (i.e.
PKM2 in mammals, PYK2 in yeast) are expressed. The
resultant accumulation of PEP causes feedback inhibi-
tion of several glycolytic enzymes, including the redox
regulator TPI, and flux in the PPP increases (Grüning
et al., 2011; Grüning et al., 2014). TPI inhibition by PEP
was required to prevent oxidative stress and oxidative
damage, and led to protein oxidation and mitochon-
drial damage in respiring cells when interrupted (Grün-
ing et al., 2011; Grüning et al., 2014). As described in
Section VIII, a similar mechanism appears to be used by
cancer cells to maintain their metabolic redox balance
as well.
(2) Transcriptional regulators of the PPP
The concerted allosteric/post-translational response
is followed by transcriptional events and transcripts
and proteins of the PPP increase in concentration
(Chechik et al., 2008). The transcriptional changes
occur in a fully coordinated manner, and enzymes are
subsequently induced depending on their molecular
function (Ihmels et al., 2004; Chechik et al., 2008).
Therefore, the strictly timed program facilitates the
cell’s reaction against minatory redox collapse imme-
diately via the metabolome and the proteome, then
later via the transcriptome, to adapt to the cellular
responsibilities (Fig. 3). Such transcriptional patterns
shape metabolic network gene regulation in response
to changing conditions due to co-expression of enzymes
that catalyse connected reactions.
The details of transcriptional regulation of PPP
enzymes varies strongly among organisms; therefore,
only principal mechanisms will be discussed here. Both
in mouse and yeast, G6PDH is transcriptionally induced
upon oxidative stress, and by the need for NADPH and
PPP intermediates for anabolic reactions such as lipid
synthesis and nucleotide synthesis (Kletzien, Harris &
Foellmi, 1994; Lee et al., 1999; Stanton, 2012). These
effects are not specific to G6PDH, other PPP enzymes
are dependent on transcriptional mechanisms as well
(Kletzien et al., 1994; Lee et al., 1999; Stanton, 2012).
This transcriptional regulators differs according to the
specific demands of the cell or tissue. For instance, PPP
regulation for lipid synthesis is achieved by the sterol
regulatory element-binding proteins (SREBPs) class
transcription factors, whereas the regulation during
oxidative stress is mediated by nuclear respiratory fac-
tor 2 (Nrf 2)-family and other transcription factors. The
latter also govern synthesis of many enzymes directly
involved in oxidative stress defence (Stanton, 2012).
In budding yeast, PPP gene expression control during
oxidative stress is also exerted by basic leucine zipper
(bZIP, Yap1) transcription factors and the nuclear
response regulator Skn7. These factors, acting either
in concert or as single regulators, govern the cellular
response not only to oxidative stress, but also when
anabolic intermediates are needed (Lee et al., 1999).
During oxidative stress, another regulatory role has
been attributed to the transcription factor Sin Three
Binding protein 5 (Stb5), which activates PPP enzymes
in response to exposure to the thiol oxidizing agent
diamide (Akache, Wu & Turcotte, 2001; Larochelle
et al., 2006; Hector et al., 2009).
(3) Feedforward regulation of the metabolome to the
transcriptome: PPP metabolites as regulators of the
stress response
During stress conditions, the PPP seems to have attained
another role: the induction of stress-responsive gene
expression. Evidence for an NADPH-independent
function of the PPP in the antioxidant response comes
from the observation that enzyme deficiencies of both
PPP branches are oxidant sensitive (Juhnke et al., 1996;
Krüger et al., 2011). Moreover, a yeast double mutant
deleted for G6PDH (Zwf1) and the non-oxidative
PPP enzyme Tal1 is more H2O2 sensitive than the
parent mutants deleted for either Tal1 or Zwf1 alone
(Krüger et al., 2011). By contrast, increased oxidant
resistance was obtained when the metabolite load
of the non-oxidative pathway was augmented due to
expression of the mammalian SHPK in yeast (Kardon
et al., 2008; Krüger et al., 2011). In addition, stress
response genes were induced when the flux of the
PPP was stimulated by genetic perturbation of glycol-
ysis (Krüger et al., 2011). Finally, tuning the NADPH
demand gradually by overexpression of an engineered
NADPH-dependent butanediol dehydrogenase led
to a concomitant accumulation of PPP metabolites
and also triggered the induction of PPP and stress
response genes (Celton et al., 2012). Hence, during
the stress response, the PPP appears to play not only
the role of a canonical metabolic pathway which
responds to oxidant treatments, but also functions as
a transcriptional balancer and is involved in inducing
components of the oxidative stress response. The exact
underlying molecular mechanisms are however yet
unknown.
IV. ANALYTICAL METHODS FOR MEASUREMENT
OF PPP INTERMEDIATES
Key to finding new PPP reactions, as well as elucidating
regulation of the pathway, are reliable methods to
quantify PPP flux and intermediate concentrations.
Major challenges of studying the PPP include the high
turnover rates of its intermediates in the second or
sub-second time range (Weibel, Mor & Fiechter, 1974;
De Koning & van Dam, 1992; Douma et al., 2010)
and low abundances of these compounds (Casazza
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& Veech, 1986). Rapid sampling techniques such as
cold methanol quenching are typically employed to
arrest metabolism immediately in cells (De Koning
& van Dam, 1992). A further difficulty in sugar phos-
phate analytics is the proper separation of pentose
isomers (ribose 5-phosphate , ribulose 5-phosphate and
xylulose-5-phosphate) and hexose isomers (glucose
6-phosphate, fructose 6-phosphate and other relevant
hexose monophosphates).
(1) From historical techniques to LC-MS/MS
A series of different methods have been developed to
study PPP metabolites and enzymes, including colori-
metric assays (Sable, 1952; Novello & McLean, 1968)
and the use of thin layer chromatography in com-
bination with 14C-labelled substrates (Becker, 1976).
Another widely used quantification approach is to cou-
ple the enzymatic interconversion of specific sugar phos-
phate substrates to the NAD-dependent oxidation of
glyceraldehyde 3-phosphate by GAPDH, or other reac-
tions catalysed by NADP(H)- or NAD(H)-dependent
enzymes, and to monitor the consumption of NAD(P)H
by spectrophotometric or fluorometric methods (Sable,
1952; Kauffman et al., 1969; Casazza & Veech, 1986;
King, Passonneau & Veech, 1990). However, these pro-
cedures are limited to measuring one component at a
time and are critically dependent on the specificity of
purified enzymes and optimal assay conditions. Detailed
studies of the PPP were therefore accompanied by long,
cumbersome analytical methods with relatively low sen-
sitivity and virtually no dynamic over time (Casazza &
Veech, 1986).
With the appearance of high-performance liquid
chromatography (HPLC) these extensive measure-
ment times could be drastically reduced to 30–180min
(Giersch, 1979; Smrcka & Jensen, 1988; Swezey, 1995),
giving rise to major advances in the field of PPP
research. A combination of chromatographic meth-
ods with mass spectrometry eventually facilitated the
routine separation and analysis of sugar phosphates.
Several capillary electrophoresis-MS (Soga, 2007) and
gas chromatography-MS methods (Koek et al., 2006;
Cipollina et al., 2009) have been developed; however,
they have already been relatively outnumbered by a
number of liquid chromatography tandem mass spec-
trometry (LC-MS/MS) techniques for sugar phosphate
measurement. In a targeted LC-MS/MS approach,
Wamelink et al., 2005 determined absolute concentra-
tions of a series of sugar phosphate intermediates by
means of HPLC and tandem mass spectrometry. Later,
analogous methods were used to measure extended
sets of metabolites (Luo et al., 2007; Buescher et al.,
2010; Jannasch, Sedlak & Adamec, 2011; Rühl et al.,
2012; Lu et al., 2010; Bajad et al., 2006). Without doubt,
mass spectrometry as the detection system has strongly
enhanced sugar phosphate analysis; but difficulties
in separating structural isomers still need to be over-
come. The development therefore of further powerful
separation procedures will be of high importance to
allow for a more reliable and robust quantification of
PPP metabolites.
In addition to measuring metabolite levels, there has
been long-standing interest in measuring PPP flux. One
classical and reliable approach to measuring absolute
oxPPP flux in cells involves feeding, in separate exper-
iments, 1-14C-glucose and 6-14C-glucose and measuring
radioactive CO2 release (Katz &Wood, 1963). As carbon
1 of glucose is selectively released by the oxPPP whereas
other pathways metabolize carbon 1 and 6 identically,
the difference in radioactive CO2 release from these
two tracers provides direct quantitation of the oxPPP
flux. Kinetic analysis of PPP intermediate labeling from
13C-glucose by LC–MS can also be used to calculate
absolute oxPPP flux and gives similar estimates to
the 14C-CO2-release approach, but the
14C-approach
remains more precise (Fan et al., 2014).
A strategy based on the cleavage of carbon 1 of
glucose by the oxPPP has also been employed to
measure oxPPP relative to non-oxPPP flux into
ribose-5-phosphate. One method involves feeding,
separate experiments, 1-13C-glucose and 6-13C-glucose
and measuring ribose-5-phosphate labeling by mass
spectrometry, with ribose-5-phosphate produced via
oxPPP labeled by 6-13C but not 1-13C-glucose. More
conveniently, one can feed 1,2-13C-glucose and to look
for singly versus doubly labeled ribose-5-phosphate,
with the former made by the oxPPP and the latter by
the non-oxPPP (Lee et al., 1998). A limitation of these
methods is that they do not distinguish between net
ribose production by the non-oxPPP versus exchange
flux (which can impact ribose-5-phosphate labeling
even if net non-oxPPP flux is away from ribose). Thus,
definitive methods for understanding non-oxPPP flux
are still needed, and additional tracers and measure-
ment of more metabolites’ labeling may, with proper
computational deconvolution, provide further insights
(Brekke et al., 2012; Tang et al., 2012; Crown et al., 2012).
In this vein, recent work has provided a new tracer
method for the PPP: Deuterium-labeled glucose (1-2H
or 3-2H-glucose) to track specifically oxPPP-produced
NADPH and its subsequent utilization for reductive
biosynthesis (Fan et al., 2014; Lewis et al., 2014). Initial
data show that the oxPPP accounts for about 50% of
total NADPH in transformed mammalian cells growing
in culture, withmost of this NADPHdevoted to fatty acid
synthesis. These methods are now poised to quantitate
variation in oxPPP activity and NADPH usage across
conditions, cell types, and compartments.
(2) In vivo PPP measurements using NMR
MS-based methods are sensitive, selective and robust,
but are not applicable in vivo. Classic nuclear mag-
netic resonance (NMR) methods regularly fall short of
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providing the sensitivity required for studying the PPP.
However, recently, a newNMR technique has been intro-
duced, termed hyperpolarization, which can increase
the sensitivity of the 13C NMR experiment by more
than 104-fold (Ardenkjaer-Larsen et al., 2003). Being
dynamic, this method could be used to measure PPP
flux in vivo. A 13C-labelled cell substrate is mixed with
a stable radical and cooled to temperatures close to
absolute zero (∼1K) in a high magnetic field (typically
3.5-5T). At this temperature the electron spins in the
radical are almost completely polarized. This polariza-
tion is then transferred to the 13C spins by microwave
irradiation and the sample is then rapidly warmed to
room temperature with substantial retention of the 13C
spin polarization. Cells can then be exposed to the
hyperpolarized 13C-labelled substrate, or for in vivo stud-
ies the tracer can be injected intravenously or added
to the growth media of microorganisms. The signal is
now boosted as a result of polarization of the 13C spins,
so that the position of the molecule and the metabo-
lites formed from it can be imaged (Brindle et al., 2011;
Kurhanewicz et al., 2011).
The major limitation of the technique is the relatively
short life time of the spin polarization (typically ∼30 s in
vivo), which means that only relatively rapid metabolic
processes can be imaged and the experiment must
be accomplished within 2–5min following injection
of the hyperpolarized substrate. Measurements with
hyperpolarized [U-2H, U-13C] glucose in E. coli, yeast
and breast cancer cells have shown production of
hyperpolarized [1-13C] pyruvate or lactate, which allows
real-timemeasurements of glycolytic flux (Meier, Jensen
& Duus, 2011a; Meier et al., 2011b; Harris, Degani &
Frydman, 2013). The technique was recently translated
to a clinical study of prostate cancer (Nelson et al.,
2013), and as discussed in Section VIII, is revealing the
activity of the PPP in human cancer cell metabolism
in vivo.
V. THE PPP IN BIOTECHNOLOGY: METABOLIC
ENGINEERING
The PPP is one of the most important targets for
metabolic engineering and biotechnology. One way in
which this pathway is utilized is as a source of NADPH
and pentose sugars for the overproduction of various
commercially and medically important compounds
such as carotenoids (Schwender et al., 1996; Mart
ínez et al., 2008), polymers (Kabir & Shimizu, 2003; Jung
et al., 2004), antibiotics (Jørgensen et al., 1995; Avi-
gnone Rossa et al., 2002; Butler et al., 2002; Li &
Townsend, 2006; Borodina et al., 2008), alcohols (Jepps-
son et al., 2002; Jeffries & Jin, 2004; Hahn-Hägerdal
et al., 2007), nucleosides (Kamada et al., 2001) and
amino acids (Marx et al., 1997; Herrmann & Weaver,
1999). Additionally, altering the PPP was used to prevent
carbon exhaust during pentose fermentation (Verho
et al., 2002). Recently, the PPP has been utilized to
create a synthetic non-oxidative glycolysis/PPP hybrid
pathway able to produce energy significantly more
efficiently by precluding carbon loss via carbon dioxide
(Bogorad, Lin & Liao, 2013) – a proof of concept that
metabolic engineering could contribute to reducing
the current exhaust of greenhouse gases.
Focus on producing the biopolymer poly-hydro-
xybutyrate (PHB), a non-toxic biodegradable and
bio-derived ‘green’ plastic (Hankermeyer & Tjeerdema,
1999), has included modification of both the oxidative
and non-oxidative enzymes of the PPP. The insertion
of gnd and tktA genes (6PGDH and TKL, respectively)
from E. coli into the facultative chemolithoautotroph
bacterium, Ralstonia eutropha, amplified gnd, which
overproduced NADPH, but also suppressed growth
as well as PHB production. Conversely, amplifica-
tion of tktA significantly increased the generation
of PHB via efficient conversion of glyceraldehyde
3-phosphate into acetyl-coenzymeA, the precursor for
PHB biosynthesis (Lee, Shin & Lee, 2003). Another
attempt focused on generating PHB via the PPP tar-
geted the oxidative pathway only. By deleting the pgi
gene in E. coli, carbon flux was shown to be redirected
through the PPP in turn increasing the production
of NADPH, creating a reducing power imbalance
and affecting cell growth. The introduction of the
NADPH-consuming PHB biosynthetic pathway into
the pgi knockout, allowed partial cell growth recovery
(Kabir & Shimizu, 2003).
Another genus where modification of the PPP was suc-
cessful in industrial application is Streptomyces, a work-
horse for the generation of various antibiotics (Hop-
wood, 2007). To overproduce the pigmented antibiotics
actinorhodin (ACT) and undecylprodigiosin (RED),
the pfkA2 gene was deleted in S. coelicolor A3(2), lead-
ing to increased flux through the PPP (Borodina et al.,
2008). Similarly, inactivation of the glycolytic genes
gap1 and gap2, encoding GAPDH, in S. clavuligerus was
exploited to increase production of clavulanic acid,
a 𝛽-lactamase inhibitor, used alongside penicillin and
cephalosporin to combat antibiotic resistance (Li &
Townsend, 2006). The overproduction of clavulanic
acid was facilitated through increasing the supply of its
precursor glyceraldehyde 3-phosphate. A recent study
proposed that in order to increase the flux towards
the PPP, TAL overexpression would be much more
useful than GAPDH inactivation, because of the com-
promised carbon balance of the PPP (Linck et al.,
2014).
Modification of the PPP has also been effective in
fungal biotechnology. The fungus Penicillium chryso-
genum was exploited by enhancing flux through the
PPP to increase NADPH levels, thereby increasing the
penicillin yield (Jørgensen et al., 1995). Other appli-
cations of the PPP in fungal biotechnology include
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the optimisation of alcohol, amino acids (e.g. lysine),
nucleosides, inosine and 5′-xanthylic acid produc-
tion (Marx et al., 1997; Kamada et al., 2001; Jeppsson
et al., 2002; Overkamp et al., 2002; Verho et al., 2002).
Hence, in several instances an altered PPP flux was
beneficial for biotechnological production cycles in
both bacteria and yeast systems via its NADPH donor
function, or inhibited to decrease carbon exhaus-
tion. Thus, altering PPP activity is exploitable in both
microbial and eukaryotic biotechnology in order to
optimize cofactor- and sugar-phosphate-dependent
processes.
VI. INBORN ERRORS WITHIN PPP ENZYMES
THAT LEAD TO HUMAN METABOLIC DISEASE
Four known metabolic genetic diseases are the direct
consequence of a deficiency in a PPP enzyme; and at
least two genetic disorders associated with the PPP are
attributed to enzyme mutations in glycolysis via affect-
ing PPP activity. Notably, these PPP disorders encompass
both the most frequent human genetic defect (G6PDH
deficiency) as well as the so-far rarest human disor-
der [ribose 5-phosphate isomerase (RPI) deficiency],
where only a single patient has been diagnosed to date.
The other defects, TAL deficiency, as well as the two
glycolytic syndromes TPI and glucose phosphate iso-
merase (GPI) deficiency, occur at a different frequency
but are considered rare disorders as well (Fig. 4).
(1) G6PDH deficiency, the most common human
enzyme defect
G6PDH deficiency (OMIM: 305900) is an X-linked dis-
order; the gene is located at the telomeric region of
the long arm of the X chromosome (band Xq28) (Cap-
pellini & Fiorelli, 2008; Van Zwieten, Verhoeven &
Roos, 2014). Prevalent in more than 400 million peo-
ple worldwide, it represents the most common her-
itable human enzyme defect (Cappellini & Fiorelli,
2008; Nkhoma et al., 2009). The global occurrence of
G6PDH deficiency is geographically correlated with
areas inhabited by populations historically exposed
to endemic malaria, including Africa, Mediterranean
Europe, South-East Asia and Latin America (Ruwende
& Hill, 1998).
The most frequent clinical manifestation is neonatal
hyperbilirubinaemia and chronic haemolytic anaemia
(Luzzatto & Mehta, 1995; Cappellini & Fiorelli, 2008;
Van Zwieten et al., 2014). The high frequency of the
disorder is likely explained as reduced G6PDH activ-
ity appears protective against malaria caused by Plas-
modium falciparum (Luzzatto & Bienzle, 1979; Ruwende
& Hill, 1998). As the oxidative PPP is the only rel-
evant NADPH source for red blood cells, a decrease
in NADPH production is likely associated with the
clinical phenotype, but potentially also explains this
anti-malaria advantage. As a consequence, however,
despite most carriers of mutant G6PDH alleles being
asymptomatic, exposure to oxidative stressors such as
artemisinin (and other drugs) or infections can elicit
acute haemolysis in G6PDH patients. As such, the epi-
demiology of G6PDH deficiency has been related to
the sickle cell anaemia phenotype, caused by Hbs and
SS variants of haemoglobin. Sickle cell anaemia is asso-
ciated with episodes of acute illness and progressive
organ damage, but is also associated with heterozygous
advantage against malaria (Rees, Williams & Gladwin,
2010).
G6PDH deficiency can be associated with a second,
rare defect in the PPP, 6-phosphogluconate dehydro-
genase (6PGDH) deficiency (Beutler, Kuhl & Gelbart,
1985). The first evidence of the enzyme deficiency was
reported in 1963, when a female patient presenting
G6PDH deficiency exhibited reduced activity of 6PGD
as well (Brewer & Dern, 1964). More recently, also
G6PDH independent incidences of this defect have
been reported, and lead to reduced redox tolerance of
erythrocytes (Caprari et al., 2001).
(2) RPI deficiency, the currently rarest human disorder
By contrast with G6PDH deficiency, other PPP disorders
are exceptionally rare. Huck et al., 2004 described a
patient with a deficiency of RPI (OMIM: 608611) who
suffered from leukoencephalopathy and peripheral
neuropathy. This patient had psychomotor retardation
from early in childhood and developed epilepsy at the
age of four. From the age of 7 the patient experienced
neurological regression, with deterioration of vision,
speech, hand coordination, walking, and seizures. Neu-
rological examination at the age of 14 years showed
spasticity, bilateral optic atrophy, and nystagmus on
lateral gaze, an increased masseter reflex and mixed
cerebellar/pseudobulbar dysarthria. He had prominent
cerebellar ataxia and mild peripheral neuropathy and
displayed severe mental retardation. The patient is now
(2014) in his twenties, and so far a unique case, as since
the original report no further cases of RPI deficiency
have been described.
The molecular diagnosis of the rare case of RPI
deficiency was facilitated through a combination of
metabolic profiling and candidate gene re-sequencing.
Magnetic resonance imaging (MRI) is able to iden-
tify brain abnormalities in children with neurological
deficits (Watkins, Gadian & Vargha-Khadem, 1999;
Huck et al., 2004). MRI of the patient showed extensive
anomalies of the cerebral white matter with prominent
involvement of the short association fibres (U-fibres),
relative sparing of periventricular white matter, and
complete sparing of corpus callosum and internal
capsule (Van der Knaap et al., 1999). Extremely high
concentrations of pentitol metabolites (arabitol and
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Fig. 4. Inherited metabolic disease caused by pentose phosphate pathway (PPP) deficiencies, including two glycolytic
enzymopathies with effects on the PPP. PPP enzymopathies are caused either by complete or partial deficiency of PPP
and glycolytic enzymes. Abbreviations are defined in Table 1, H6PDH, hexose 6-phosphate dehydrogenase.
ribitol) were found in the brain by magnetic res-
onance spectroscopy (MRS), and in cerebrospinal
fluid, plasma and urine, as well as xylulose in the
urine as tested by mass spectrometry (Van der Knaap
et al., 1999). These metabolites can derive from PPP
intermediates xylulose, ribose 5-phosphate and ribu-
lose 5-phosphate, which guided to the identification
of the candidate gene by targeted re-sequencing of
PPP enzymes. Two mutant alleles in the RPI encod-
ing RPIA gene were demonstrated: a 1 bp deletion
(540delG) resulting in a frameshift at codon 181
and a predicted truncated protein of 196 amino
acids, and a missense mutation C182T, resulting in
an Ala-to-Val substitution (A61V). The finding of two
mutant alleles in the patient with apparently healthy
parents suggests autosomal recessive inheritance.
Genetic and biochemical evidence suggests an expla-
nation for the rareness of the case: full RPI deficiency
appears to be lethal. Studies of patient-derived cell
lines and transgenic yeast models however revealed
that the patient carried an uncommon allelic combi-
nation: he is heterozygous for a catalytically inactive
RPI allele, whereas the second allele encodes a par-
tially catalytically functional enzyme that exhibits a
cell-type-dependent expression deficit in addition
(Wamelink et al., 2010).
(3) TAL deficiency
Transaldolase deficiency (TAL or TALDO deficiency,
OMIM: 606003) is caused by autosomal recessive defi-
ciency in the human TAL-encoding gene (TALDO1)
located on chromosome 11p15.5–p15.4, and has
recently been diagnosed in more than 30 patients
worldwide (Wamelink et al., 2007; Wamelink et al.,
2008a; Tylki-Szyman´ska et al., 2009; Balasubramaniam
et al., 2011; Eyaid et al., 2013). TAL-deficient patients
suffer from great phenotypic variability. Most patients
display first symptoms in the neonatal or antenatal
period, with prenatal intra-uterine growth retardation,
oligohydramnios and hydrops foetalis being described
(Valayannopoulos et al., 2006). Newborns present with
hepatosplenomegaly, bleeding diathesis, abnormal
liver function, cholestatic jaundice and elevated liver
enzymes, while in older patients, hepatic fibrosis or cir-
rhosis is the pathological liver hallmark. Most patients
show haemolytic anaemia, dysmorphic features, neona-
tal oedema and congenital heart defects. Moreover,
renal manifestations and endocrine disorders have
been frequently reported (Loeffen et al., 2012). Mild
transient hypotonia was described in several patients
but mental and motor development was normal in
most patients. Recently, a TAL-deficient patient with
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early onset hepatocellular carcinoma with an 9 years
old asymptomatic older brother were described (Leduc
et al., 2013).
TAL deficiency results in the accumulation of seven-
carbon sugars (sedoheptulose, mannoheptulose), sedo-
heptulose 7-phosphate, and open chain sugar-alcohols
(polyols) including erythritol, arabitol, ribitol, sedo-
heptitol and perseitol, and erythronic acid derived
from the pathway intermediates (Verhoeven et al., 2001;
Wamelink et al., 2005; Engelke et al., 2010) that can
help as biomarkers in diagnosis. The clinical picture of
TAL deficiency is dominated by liver fibrosis/cirrhosis,
resulting in permanent scar tissue. Since TAL has been
recognized as a regulator of apoptotic signal-processing
(Banki et al., 1996), this might have relevance for the
pathogenesis of liver disease, as observed in patients
and in TAL-deficient mice (Perl et al., 2011). In addi-
tion, accumulation of the metabolite sedoheptulose
7-phosphate has been suggested to be involved in
the pathophysiology of liver cirrhosis (Verhoeven et al.,
2001), and could be functionally connected to the dis-
ease phenotype.
In a mouse model of TAL-deficiency, the accumu-
lation of sedoheptulose 7-phosphate and a failure to
recycle ribose 5-phosphate through the non-oxidative
branch has been observed. Furthermore, diminished
production of NADPH led to secondary depletion of
reduced glutathione (GSH) and oxidative stress, as well
as loss of the mitochondrial transmembrane poten-
tial and mitochondrial mass (Hanczko et al., 2009).
A decrease of NADPHwas potentially caused by the con-
version of five-carbon sugar phosphates to five-carbon
polyols by aldose reductase at the expense of NADPH
levels (Perl et al., 2011). In some earlier diagnosed
TAL-deficient patients, low levels of cholesterol, estra-
diol, testosterone or vitamin D were detected, indicating
decreased NADPH/NADP+ and leading to decreased
activity of NADPH-dependent reactions (i.e. cholesterol
biosynthesis, hormonemetabolism) (Banki et al., 1996).
Haemolytic anaemia was also observed in most patients,
probably related to decreased NADPH production in
erythrocytes as observed in G6PDH deficiency.
(4) GPI deficiency
GPI catalyses the interconversion of glucose 6-
phosphate to fructose 6-phosphate. A deficiency in
this enzyme (OMIM: 613470) increases the flux in
the PPP, as the glycolytic route of carbon metabolism
becomes inhibited. Deficiency of erythrocyte GPI was
first described in a boy with lifelong nonspherocytic
anaemia in 1968 (Baughan et al., 1968). In a patient
diagnosed in 1985, the GPI deficiency syndrome was
characterized by a deficiency in red cells, granulocytes
and muscles (Schröter et al., 1985). In 1993, another
case of GPI deficiency was associated with hereditary
nonspherocytic haemolytic anaemia (Shalev et al.,
1993). Mutations found in GPI deficiency retain resid-
ual activity of the enzyme, but the deficient enzymes
were characterized by reduced thermostability (Kugler
& Lakomek, 2000). The decreased activity of the iso-
merase causes an increase in glucose 6-phosphate,
erythrose 4-phosphate and 6-phosphogluconate, indi-
cating increased metabolite load and flux in the PPP.
In yeast cells grown on glucose, a full deficiency of GPI
is lethal, but can be complemented by the overexpres-
sion of NADPH-oxidising enzymes. This indicates that
the fatality of a full GPI deficiency results from redox
cofactor imbalance due to NADPH overproduction in
the PPP (Verho et al., 2002).
(5) TPI deficiency
TPI deficiency (OMIM: 615512) was one of the first
enzymatic defects to be associated with the PPP.
Schneider et al., 1965 reported a deficiency of the
enzyme in red blood cells referring to the disorder as
Dacie’s type II haemolytic anaemia. TPI deficiency is
further of historical importance in the treatment of
rare diseases, as it was an early case where an enzyme
replacement therapy was applied (Ationu et al., 1999).
TPI deficiency is a rare and severe disease involving
nonspherocytic haemolytic anaemia, leading to pro-
gressive neuronal degeneration, muscle degeneration
and is associated with deadly infections and spasticity.
In most cases, the affected children die before adult-
hood (Schneider, 2000; Orosz et al., 2009). Since the
discovery of the syndrome less than 100 patients have
been diagnosed worldwide (Schneider & Cohen-Solal,
1996). This frequency is lower than the natural muta-
tion rate would predict, but also lower as predicted
from the estimated population frequencies of recessive
TPI-deficient alleles. This indicates that homozygously
defective alleles are embryonically lethal, a notion
supported by studies in mice (Merkle & Pretsch, 1989).
The substantial frequencies of heterozygote TPI defi-
ciency lead to speculations of a heterozygous advantage
of TPI-deficient alleles (Mohrenweiser, 1981; Mohren-
weiser, Wurzinger & Neel, 1987; Watanabe, Zingg &
Mohrenweiser, 1996). In a more recent study, the
entire TPI locus was re-sequenced in 387 centenarians,
and single nucleotide polymorphisms (SNPs) were
genotyped in an even larger sample of long-lived indi-
viduals (N = 1422) and younger controls (N = 967).
However, no heterozygous TPI deficient alleles were
confirmed (Ralser et al., 2008). The discrepancy could
indicate that the observed differences in TPI activity
had an epigenetic or post-translational cause, or that
high frequencies of heterozygous TPI null alleles are a
population-specific phenomenon.
Despite a substantial number of TPI-deficient alle-
les having been described (Schneider & Cohen-Solal,
1996), a single allele describes the majority of clini-
cal cases. This allele carries a mutation exchanging a
glutamic acid residue on position 105 (position 104
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when not counting the ATG codon), to an aspartic
acid, located in the region of the TPI enzyme respon-
sible for dimer formation (Arya et al., 1997; Schneider,
2000; Rodríguez-Almazán et al., 2008). This allele has
been the only one described to cause TPI deficiency in
the homozygous state, and it was speculated that the
allele may descend from a single individual that may
have lived in what is now France or England around
1000 years ago (Arya et al., 1997). Recently, the same
allele has also been found in a Turkish family, but it is
currently unclear whether it results from a de novomuta-
tion (Sarper et al., 2013). It has been discovered in a
transgenic yeast model expressing the human isoform
that this residue substantially interferes with the dimeri-
sation of TPI, but does not per se interfere with catalysis
(Ralser et al., 2006). The global structure of TPIE104D
is similar to that of the wild-type; however, residue 104
is part of a conserved cavity that possesses an elabo-
rate conserved network of buried water molecules at
the dimer interface (Rodríguez-Almazán et al., 2008).
In the TPIE104D mutant, a disruption of contacts of the
amino acid side chains in the conserved cluster leads
to a perturbation of the water network in which the
water–protein and water–water interactions joining the
two monomers are significantly weakened and dimin-
ished (Rodríguez-Almazán et al., 2008).Hence, TPI defi-
ciency is primarily caused by a structural defect.
How does TPI deficiency, a disorder caused by a struc-
turally defective glycolytic enzyme, then relate to the
PPP? In the course of generating a yeast model for
TPI deficiency, it was discovered that TPI alleles with
reduced catalytic activity render cells resistant to oxi-
dants (Ralser et al., 2006). In yeast, this was mainly
described for thiol-oxidizing reagents such as diamide,
however in Caenorhabditis elegans sensitivity was observed
also for natural oxidants including juglone (Ralser et al.,
2007). Cells expressing the mutant TPI alleles pos-
sess increased concentration of PPP metabolites, and
the antioxidant effects of TPI mutant alleles are fully
dependent on the first enzyme of the oxidative PPP,
G6PDH (Ralser et al., 2007; Grüning et al., 2011; Grün-
ing et al., 2014). In Drosophila melanogaster , the situation
seems to be more complex and dependent on respi-
ratory activity of the TPI mutant cells. Also Drosophila
melanogaster cells’ TPI mutations affect oxidant resis-
tance, however their redox status seem to shift towards
oxidation (Hrizo et al., 2013). Moreover, as shown below
(Section VIII), TPI mutant alleles were important in
understanding the role of the PPP’s antioxidant activity
in cancer.
(6) Hexose 6-phosphate dehydrogenase (H6PDH)
deficiency
H6PDH is a luminal enzyme analogous to G6PDH
responsible for NAD+ and NADP+ reduction in the
endoplasmic reticulum. The enzyme oxidizes glucose 6-
phosphate, glucose, galactose 6-phosphate and 2-
deoxyglucose 6-phosphate (Krczal, Ritter & Kömpf,
1993; Senesi et al., 2010). Several allelic variants
of H6PDH mutations are known and result in hir-
sutism, oligomenorrhoea, obesity, acne and infertility
(Jamieson et al., 1999; Draper et al., 2003; Lavery et al.,
2008). Draper et al., 2003 hypothesized that mutations
in H6PDH could cause an NADPH deficiency in the
endoplasmic reticulum (ER), affecting the direction-
ality of the 11-beta-hydroxysteroid dehydrogenase type
1 (HSD11B1) reaction. HSD11B1 is a regulator of
the tissue-specific glucocorticoid availability in corti-
sone reductase deficiency (OMIM: 604931) (Draper
et al., 2003). Indeed, in a study conducted on four
patients suffering from cortisone reductase deficiency,
four novel and one known mutations in the H6PDH
gene in homozygous or compound heterozygous state
were identified. Expression data on these mutations
revealed loss of H6PDH function (Lavery et al., 2008).
Mouse models carrying the H6PDH mutations develop
fasting hypoglycaemia, increased insulin sensitivity
and increased basal and insulin-stimulated glucose
uptake (Lavery et al., 2008). It was observed that cortisol
reductase deficiency presents a similar phenotype to
polycystic ovary syndrome (POS). Furthermore, the
H6PDH gene was associated with multiple sclerosis
(Alcina et al., 2010).
VII. HOST–PATHOGEN INTERACTIONS: THE
ROLE OF THE PPP IN INFECTIOUS DISEASE
(1) The PPP as a target in parasitic protozoa
Protozoan parasites are responsible for a considerable
number of debilitating infections that affect a significant
number of people around the world, most commonly
in developing countries. These protozoa include the
kinetoplastids Trypanosoma brucei, Trypanosoma cruzi
and Leishmania spp. These parasitic protozoa cause
sleeping sickness, Chagas’ disease and leishmaniasis
(cutaneous, visceral and mucosal), respectively. Var-
ious species of the Aconoidasida genus Plasmodium
are responsible for malaria, while the archeamoeban
(amitochondriate) parasite Entamoeba histolytica is the
causative agent of amoebiasis, a disease characterized
by diarrhoea (amoebic colitis) or abscesses principally
of the liver. The biology behind the host–parasite rela-
tionship, the infection process and in some cases, even
to identify drug targets, is highly dependent on parasite
metabolism. Parasite metabolic reconfiguration and
mutations in their enzymes may contribute towards
resistance to drug treatment as well as parasite evasion
of the host innate immune response. One important
way the host immune system counteracts parasite infec-
tion is via the generation of hydrogen peroxide and
other oxidants. Due to its function in maintaining the
supply of the antioxidant cofactor NADPH, the PPP is
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therefore of great importance to the pathology of these
parasites, becoming an attractive target for drug design.
(a) Kinetoplastids, the trypanothione pathway and the
compartmentalization of the PPP in glycosomes
Kinetoplastids have a complete and functional PPP.
Studies in both T. cruzi (Igoillo-Esteve et al., 2007) and
Leishmania mexicana (Maugeri et al., 2003) have shown
that the PPP metabolized 5–10% of total glucose. Most
of the canonical PPP enzymes have homologues in these
parasites and have been cloned, characterized and crys-
tallized in at least one of the trypanosomatids (Fig. 5A)
(Barrett et al., 1994; Phillips et al., 1998; Duffieux et al.,
2000; Veitch et al., 2004; Igoillo-Esteve & Cazzulo, 2006;
Stern et al., 2007; Stoffel et al., 2011; Kaur et al., 2012).
Exceptions include TAL and RPE, for which less infor-
mation is available (Cronín, Nolan & Voorheis, 1989;
Igoillo-Esteve et al., 2007). However, these PPP enzymes
could be important for the infection process. It has been
observed that bloodstream forms (host stage) in T. bru-
cei have neither TKL nor RPE activities; hence, at this
stage, they are not capable of forming glyceraldehyde
3-phosphate from the non-oxidative branch of the PPP
(Cronín et al., 1989).
The enzymes of the PPP in these parasites are mainly
cytosolic. However, they have also been allocated to
the glycosome, the trypanosomatids’ peroxisome,
that contains the major part of the glycolytic pathway
(Hannaert et al., 2003). The role of the PPP enzymes
in the glycosome appears to be: (i) the exchange
of intermediates with the glycolytic pathway; (ii) the
supply of ribose 5-phosphate for nucleotide biosyn-
thesis, which also occurs in the glycosome; and (iii)
the supply of NADPH for the antioxidant system (try-
panothione reductase) that has also been detected
in the glycosome (Hannaert et al., 2003). In turn,
one of the main functions of the PPP in the cytosol
is the supply of reducing power (NADPH) to the
antioxidant system. In the trypanosome, antioxidant
action relies on an alternative molecule, trypanoth-
ione [T(SH)2; N
1-N8-bisglutathionylspermidine], an
analogue of glutathione. Together with its reducing
enzyme trypanothione reductase (TryR), trypanothione
replaces all the functions that the system glutathione
(GSH)/glutathione reductase (GR) has in other cells
(Olin-Sandoval, Moreno-Sánchez & Saavedra, 2010).
The major part of the antioxidant system in trypanoso-
matids therefore depends on trypanothione, and its
reduction requires NADPH equivalents supplied by the
PPP (Barrett, 1997). Due to the central role of the PPP
in antioxidant metabolism, several studies have focused
on the regulation of PPP enzymes under oxidative
stress. It has been demonstrated that G6PDH increases
its activity 46-fold in metacyclic trypomastigotes of
T. cruzi (infective form) exposed to 70 μM H2O2, an
increase related to an increment in protein content. By
contrast, epimastigotes (insect form) exposed to 20 μM
of H2O2 had decreased G6PDH activity and protein
content, an observation which can be explained with
the reasoning that under physiological conditions,
epimastigotes are not exposed to oxidative stress
(Igoillo-Esteve & Cazzulo, 2006). These results demon-
strate that oxidative stress not only regulates the activity
of G6PDH kinetically but also at the protein level.
RNAi-mediated knock-down of G6PDH in blood-
stream forms of T. brucei promoted a negative effect
on parasite growth, suggesting an essential function for
this enzyme (Cordeiro, Thiemann & Michels, 2009).
This PPP enzyme appears to be associated with the
antioxidant machinery of the parasite T. brucei partially
depleted of G6PDH are sensitive to H2O2 (Gupta
et al., 2011). Moreover, PPP flux in Leishmania mexicana
increases when the parasites are exposed to methylene
blue causing oxidative stress, providing further sup-
port that the PPP is highly essential in these parasites’
response to oxidative conditions (Maugeri et al., 2003).
The importance of the PPP in the response to oxidative
stress in trypanosomes has also been corroborated
by dynamic modelling. Recently, a kinetic model of
glycolysis in Trypanosoma brucei (Albert et al., 2005;
Achcar et al., 2012) was extended with PPP reactions
(Kerkhoven et al., 2013). Both models predicted that
the flux through the cytosolic PPP was regulated by
oxidative stress. Under low-oxidative-stress conditions
the flux through this pathway was very low. How-
ever, the simulation of oxidative stress promoted an
increase in the flux through glucose 6-phosphate
dehydrogenase/hexose 6-phosphate dehydroge-
nase, 6-phosphogluconolactonase (PGL) and ribose
5-phosphate isomerase (RPI) of about seven-, 5.5- and
4-fold, respectively. After the stress, a steady state was
predicted to be reached after 1min (Kerkhoven et al.,
2013).
6PGDH in T. brucei is essential (Barrett, 1997;
Kerkhoven et al., 2013). The lethal phenotype has been
attributed to the accumulation of 6-phosphogluconate
inhibiting PGI (Barrett, 1997), a result that has been
challenged by (i) the observation that fructose supple-
mentation, which enters glycolysis after PGI, does not
rescue the cells from death, and (ii) a lack of support
from dynamic modelling (Kerkhoven et al., 2013).
Mutations in TKL (null mutants), by contrast, do
not have any effect on cell growth, nor were changes
in morphology detected (Stoffel et al., 2011). Metabo-
lite analysis of these mutants showed that the sub-
strates ribulose 5-phosphate, ribose 5-phosphate and
xylulose 5-phosphate had accumulated 7.9-fold with
a concomitant decline in the product sedoheptulose
7-phosphate. Additionally, intracellular concentration
of 2,3-bisphosphoglycerate, phosphoenolpyruvate, fruc-
tose 6-phosphate and glyceraldehyde 3-phosphate were
reduced 2-, 4.5-, 1.5- and 3.2-fold, respectively (Stoffel
et al., 2011). Consequently, taken together, these results
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Fig. 5. The pentose phosphate pathway (PPP) in parasitic protozoa (left) and bacterial infection (right). In kineto-
plastids (A), PPP enzymes are localised in the cytosol and glycosomes (*). Plasmodia (B) have a bifunctional enzyme
(glucose 6-phosphate dehydrogenase 6-phosphogluconolactonase; GluPho) that has the activity of glucose 6-phosphate
dehydrogenase (G6PDH) and 6-phosphogluconolactonase (6PGL). Entamoeba histolytica lacks G6PDH and transaldolase
(TAL), however has developed an alternative hexose–pentose interconversion pathway (C) in which the enzymes trans-
ketolase (TKL), fructose-bisphopshate aldolase (FBA) and pyrophosphate dependent-phosphofructokinase [(PPi)PFK]
are involved. The activity of the PPP pathway is modulated by metabolites that respond to oxidants (i.e. H2O2
or paraquat); oxidant-responsive enzymes; or by the glutathione/glutathione disulfide (GSH/GSSG) ratio. 6PGDH,
6-phosphogluconate dehydrogenase. During bacterial lipopolysaccharide (LPS) infection of the mammalian intestine,
sedoheptulokinase (SHPK) is of reduced activity in the host (D) and leads to macrophage M1 polarization. In bacteria
(E), sedoheptulose 7-phosphate isomerase (SHI) and arabinose 5-phosphate isomerase (API) enzymes can increase LPS
production. O2
−: superoxide.
indicate that a main role of the PPP in trypanosomatids
appears to be in defence against oxidative stress.
(b) Plasmodium spp.
Plasmodium spp. parasites possess a complete and
functional PPP (Preuss, Jortzik & Becker, 2012). This
has been confirmed through in silico analysis, using
transcriptome profiles collected hourly during the
intra-erythrocytic cycle of the parasite. Both branches
of PPP are active at least at 50 hours post-invasion
of the erythrocyte and their expression varies most
likely due to cell requirements, such as ribonucleotide
synthesis or NADPH and ATP demand (Bozdech &
Ginsburg, 2005). The canonical PPP enzymes such as
TKL and RPI have been cloned and characterized in
P. falciparum (Holmes et al., 2006; Joshi et al., 2008).
Interestingly, Plasmodium spp. possess fusion enzymes
within the PPP. One well-studied example is a pro-
tein that combines G6PDH and 6PGL activities in a
single enzyme, glucose 6-phosphate dehydrogenase
6-phosphogluconolactonase (GluPho) (Fig. 5B). This
enzyme is regulated by S-gluthathionylation, sug-
gesting that the glutathione/ glutathione disulfide
(GSH/GSSG) ratio regulates GluPho activity (Jortzik
et al., 2011). The fusion protein is not the exception,
and multiple independent fusions of G6PDH with
other PPP enzymes have been found in this plasmodial
parasite, indicating that pathway efficiency is potentially
increased by channelling metabolites in this manner
(Stover, Dixon & Cavalcanti, 2011).
Plasmodial parasites are continuously exposed to
oxidative stress during the life-cycle stage in the ery-
throcyte; as they take haemoglobin into their acid
Biological Reviews (2014) 000–000 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
20 A. Stincone and others
food vacuole, Fe2+ is oxidised to Fe3+ and super-
oxide anions are produced, which in turn promote
the formation of H2O2 and hydroxyl radicals. The
reductases involved in these parasite’s antioxidant sys-
tems are NADPH-dependent glutathione and thiore-
doxin reductases (Müller, 2004). Although the parasites
have the enzymes isocitrate dehydrogenase and gluta-
mate dehydrogenase, which are also able of supplying
NADPH to the cell, the former enzyme generally oxi-
dizes this cofactor and the latter has been demonstrated
not to be an NADPH supplier for antioxidant systems
(Preuss et al., 2012). Furthermore, ribose 5-phosphate
can be obtained from the uptake and degradation of
host purines in contrast to being obtained from the PPP.
Thus, themain role of the PPP in Plasmodium spp. seems
to be to supply NADPH.
The role of the PPP in P. falciparum is indispens-
able during parasite infection. The parasite’s pathway
contributes to 82% of total PPP activity in infected red
blood cells (IRBCs) and 72% inG6PDH-deficient IRBCs
(Atamna, Pascarmona & Ginsburg, 1994). The highest
NADPHdemand appears when the parasite has reached
maturation (trophozoite stage) in IRBCs, which is
consistent with an increase in G6PDH activity in IRBCs
during this period (Atamna et al., 1994). As discussed in
Section VI.1, G6PDH-deficient hosts (46% females het-
erozygous; 58%males hemizygous) have increased resis-
tance to malaria (Cappellini & Fiorelli, 2008). Although
this resistance is not fully understood, two hypotheses
have been proposed: one suggests that the oxidative
stress in G6PDH-deficient erythrocytes may be the cause
of impaired infection; the other proposes that these
infected erythrocytes are more easily recognized and
destroyed by the host’s immune system (Müller, 2004).
(c) The alternative PPP of Entamoeba histolytica
An alternative PPP is found in the parasite, Enta-
moeba histolytica. This parasite lacks G6PDH, 6PGDH
and TAL (Barrett, 1997; Husain et al., 2012) and has
developed an alternative hexose–pentose interconver-
sion pathway for the formation of pentose phosphates.
This alternative pathway is constituted of several reac-
tions catalysed by TKL, FBA and phosphofructokinase
(PPi-dependent) (Susskind, Warren & Reeves, 1982)
(Fig. 5C).When Entamoeba histolytica is exposed to oxida-
tive stress, metabolites of the non-oxidative branch of
the PPP, glycerol and chitin biosynthesis are increased,
a process attributable to an inhibition of glycolytic
enzymes which, in turn, promotes redirection of the
carbon flux (Husain et al., 2012). Thus, although the
oxidative branch is absent from the PPP in this parasite,
it seems that the non-oxidative pathway still responds
to the presence of oxidative stress. This observation is
analogous to budding yeast, where the non-oxidative
PPP plays an NADPH-independent role in the stress
response too (Krüger et al., 2011).
(2) The PPP in bacterial infection
Similar to eukaryotes, the PPP and glycolysis (together
with overlapping reaction sequences such as the
Entner–Doudoroff pathway) constitute core carbon
metabolism in bacteria (Sprenger, 1995). As in eukary-
otes, the PPP is required to provide NADPH equivalents,
nucleotides and sugar phosphate precursors. An impor-
tant additional function however concerns the provision
of sedoheptulose 7-phosphate for the initiation of
lipopolysaccharide (LPS) biosynthesis (Taylor et al.,
2008). Moreover, the PPP appears to be the only path-
way allowing bacteria to utilize sugars such as d-xylose,
d-ribose, and l-arabinose, which cannot be catabolised
by other means (Wood, 1985; Sprenger, 1995; Lin,
1996). Here we briefly introduce the role of the PPP in
the bacterial infection process and the importance of
this pathway for both host and pathogen.
(a) The PPP is required in the host response to fight microbial
infection
The invasion of host cells gives rise to the activation
of defence mechanisms required for survival and
pathogen expulsion. The host response is characterized
by microbial sensors activating signalling pathways
and inducing effector mechanisms (Nish & Medzhi-
tov, 2011). Macrophages are responsible for the host
immune response by inducing signalling modules and
alterations in cell morphology and metabolic function
(Martinon, Mayor & Tschopp, 2009; Haschemi et al.,
2012). The cellular reprogramming utilizes metabolic
adaptation in response to environmental changes.
Nevertheless, there is only limited knowledge of the
bioenergetic rearrangement that takes place during
macrophage activation. Recently SHPK [formerly
carbohydrate kinase- like (CARKL)] has been identi-
fied as a modulator of macrophage regulation during
LPS-induced infection (Haschemi et al., 2012). Reduced
SHPK expression was observed in both in vivo and in
vitro experiments and associated with macrophage type
1 (M1) polarization. By contrast, SHPK overexpression
induced a pro-inflammatory response, characterized
by the presence of nuclear factor kappa-B (NF-𝜅B),
and an increase in the production of intracellular
superoxide radicals (probably due to sustained sedo-
heptulose 7-phosphate formation), which is similar
to the neutrophil-induced response (Haschemi et al.,
2012) (Fig. 5D).
Neutrophil activation characterizes the immune
response in the Gram-negative bacterium Helicobacter
pylori, the agent causing chronic gastritis and peptic
ulcer disease (Nielsen et al., 1994; Basso, Plebani &
Kusters, 2010). H. pylori was the first microorganism
to be directly associated with stomach carcinogenesis
(Sipponen & Hyvärinen, 1993). It was suggested that,
following H. pylori infection, neutrophil activation
rapidly increases ROS production (Obst et al., 2000).
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Moreover, GSH availability, normally high in the stom-
ach, is rapidly depleted after H. pylori infection of the
human gastric mucosa, mainly because GSH is used for
repairing oxidative DNA lesions in gastric carcinogen-
esis (Shirin et al., 2001; Basso et al., 2010). By contrast,
GSH levels were increased in mouse model infections,
leading to the hypothesis that the GSH (and the oxida-
tive PPP, regulating GSH synthesis) could be directly
involved in the response to the oxidative stress induced
by H. pylori infection (Matthews & Butler, 2005).
(b) The PPP is a central pathway for bacterial infection and
LPS biosynthesis
The infection process requires rapid adaptation of intra-
cellular and extracellular bacteria, involving reconfigu-
ration of their central carbonmetabolism. This is caused
predominantly by their newly encountered physical con-
ditions and nutrient availability (Eisenreich et al., 2010;
Swanepoel & Loots, 2014). More precisely, pathogens
need to modulate their metabolism and coordinate
their life cycle in order to develop specific virulence fac-
tors (Ray et al., 2009; Eisenreich et al., 2010).
Due to the presence of different microenvironments
(or niches), the host environment is character-
ized by the availability of several nutrient sources
(Brown, Palmer & Whiteley, 2008). For example,
enterohaemorrhagic (EHEC) and uropathogenic
(UPEC) Escherichia coli strains (causing haemolytic
colitis and urinary tract infection, respectively), differ
in their ability to cause infection according to their
localization (i.e. nutrient availability) (Alteri & Mobley,
2012). The mammalian urinary tract is characterized
by the presence of amino acids and small peptides,
therefore mutations in the genes coding for the PPP
and glycolytic enzymes do not affect the pathogenicity
of the UPEC E. coli. On the other hand, EHEC E. coli
needs to up-regulate both glycolysis and PPP in order
to colonize the host intestine, due to the high levels
of glycogen available which can be used as an external
carbon source (Alteri & Mobley, 2012).
Last but not least, the PPP has been found to play
an essential role in the biosynthesis of lipopolysac-
charides (LPSs). LPS is part of the external layer of
Gram-negative bacteria and is involved in not only
bacterial protection but also in the activation of the
host immune response (Raetz & Whitfield, 2002).
The biosynthesis of LPS has been intensively studied
in order to provide new therapeutic agents against
Gram-negative pathogens (Wang & Quinn, 2010). One
of the possible targets for drug discovery is SHI, as
characterized in E. coli, Pseudomonas aeruginosa (Tay-
lor et al., 2008) and H. pylori (Sarkar et al., 2012).
This enzyme converts sedoheptulose 7-phosphate
from the PPP into the lipopolysaccharide precursor
glycero-manno-heptose 7-phosphate (Kneidinger et al.,
2001; Valvano et al., 2002; Taylor et al., 2008), and has
therefore become a central target for the development
of new antibiotics and adjuvants. Further investigations
on the LPS biosynthetic pathway highlighted another
enzyme involved in the pathogenicity of an E. coli
UPEC strain, arabinose 5-phosphate isomerase (API),
which converts the PPP sugar ribulose 5-phosphate into
the LPS precursor arabinose 5-phosphate (Mosberg
et al., 2011) (Fig. 5E), emphasizing these PPP enzymes
as attractive targets for the development of future
antibiotics.
VIII. THE ROLE OF THE PPP IN CELL
PROLIFERATION AND STEM CELLS
Cell growth necessitates biosynthesis of the required
intermediates, such as nucleotides, amino acids, and
lipid precursors. Consequently, when proliferation
is induced, cells restructure their central carbon
metabolism in order to adapt to the rise in metabolic
demands. This metabolic reconfiguration includes the
shuffling of the energy flux outside the mitochondria
to fuel glycolysis and the PPP (Levine & Puzio-Kuter,
2010; Vander Heiden et al., 2010; Grüning & Ralser,
2011; Yamamoto et al., 2014). The PPP playing a crucial,
non-redundant role in the supply of building blocks
such as ribose 5-phosphate, the molecular backbone
of nucleic acids, is consequently of central importance.
Indeed, a key feature of the metabolic transforma-
tion events accompanying cellular proliferation is the
enhancement of biosynthetic capacity. Hence, diverting
the energy flux towards the non-oxidative branch of
the PPP has the key advantage of enabling the needed
nucleotide biosynthesis through the production of
ribose 5-phosphate (Deberardinis et al., 2008). In addi-
tion, this metabolic restructuring safeguards the cellular
redox balance, by modulating NADPH production in
the PPP.
Human pluripotent stem cells (PSCs), including
embryonic stem cells (ESCs) (Thomson et al., 1998) and
induced pluripotent stem cells (iPSCs) (Takahashi et al.,
2007), are of particular interest in biomedicine given
their ability to proliferate indefinitely (self-renewal) and
to differentiate into virtually any cell type of the body
(pluripotency). The central importance of metabolism
in reprogramming and self-renewal has recently caught
the attention of the stem cell community, with most
discoveries dating back to recent years only (reviewed in
(Folmes et al., 2012; Zhang et al., 2012; Xu et al., 2013;
Bukowiecki, Adjaye & Prigione, 2014) and has revealed
that the induction and maintenance of PSCs is associ-
ated with a profound change of anabolic demands. PSCs
exhibit an elevated rate of proliferation and distinct cell
cycle features compared to common somatic cells (Ruiz
et al., 2011). Moreover, PSCs are particularly sensitive to
redox imbalance (Saretzki et al., 2008) and display low
levels of oxidatively modified proteins, lipids, and DNA
(Prigione et al., 2010). Indeed, increased ROS levels
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have been shown to promote differentiation (Yanes
et al., 2010).
The establishment of the proliferative PSC state
has been found to be coupled with elevated lac-
tate generation and enhanced glycolytic flux (Pri-
gione et al., 2010; Folmes et al., 2011). Moreover,
upon glycolysis-activating conditions, such as under
hypoxia stimulation or after treatment with small-
molecule inducers of the master metabolic regulator
hypoxia-inducible transcription factor 1 (HIF-1) (see
section VIII-4-d), the efficiency of somatic cell repro-
gramming is significantly improved (Yoshida et al., 2009;
Zhu et al., 2010). Conversely, genetic ablation of HIF-1
hampers the formation of iPSCs (Prigione et al., 2013;
Mathieu et al., 2014). Finally, increased expression of
the pyruvate kinase isozyme M2 (PKM2), which regu-
lates the flux distribution between glycolysis and the
PPP (section VIII-3), has been identified in both ESCs
and iPSCs compared to somatic cells (Prigione et al.,
2013).
Currently, evidence from altered PPP metabolism in
stem cell populationsmainly originates from the analysis
of their gene expression profiles. Genes regulating the
first steps of glycolysis were up-regulated in PSCs
compared to somatic cells, including glucose uptake
(SLC2A3) and glucose phosphorylation to glucose
6-phosphate (HK3 and GCK) (Prigione et al., 2011;
Varum et al., 2011). Enzymes of the final steps of gly-
colysis (such as PGAM2, ENO, PKLR , and LDH) are
up-regulated in PSCs. On the other hand, the expres-
sion level of the glycolytic enzymes downstream of
glucose 6-phosphate, including GPI, PFK, and ALDO,
is reduced in PSCs, while the level of genes involved in
the non-oxidative branch of the PPP (RPIA and TKT)
is augmented (Folmes et al., 2011; Prigione et al., 2011;
Varum et al., 2011). Hence, the transcriptional data
of PSCs suggest that glycolytic intermediates may be
diverted into the PPP, in order to support both the
biomass accumulation and redox homeostasis that are
associated with themaintenance and derivation of PSCs.
Accordingly, LC-MS/MS-based metabolite quantifica-
tion detected the accumulation of glucose 6-phosphate
and decreased dihydroxyacetone phosphate in PSCs
compared to fibroblasts (Prigione et al., 2011), which
may be indicative of overall increased metabolic activity
due to proliferation and possibly specific PPP activation.
Elevated protein expression of hexokinase II (HXK2),
which causes a higher glycolytic rate than isoform I,
has also been observed in the mitochondria of PSCs
(Varum et al., 2011). This is of particular interest since
HXK2 activity may be stimulated under hypoxia by the
p53-inducible target TP53-induced glycolysis and apop-
tosis regulator (TIGAR) (see sectionVIII-4-a) to induce
the PPP and preserve redox homeostasis (Cheung,
Ludwig & Vousden, 2012).
Finally, the importance of the PPP for the mainte-
nance of the pluripotent state is supported by the find-
ings that G6PDH-depleted ESCs proliferate at a reduced
rate and, upon oxidant exposure, are incapable of
increasing the PPP flux, thus resulting in apoptotic cell
death (Filosa et al., 2003; Fico et al., 2004). Furthermore,
genetic or small-molecule-based inhibition of the PPP
forces PSCs to exit the self-renewal state and start the
differentiation process (Manganelli et al., 2012). Over-
all, it appears that promoting the activation of the PPP
is functionally critical to support the establishment and
the maintenance of the proliferative conditions asso-
ciated with the undifferentiated PSC state. It is how-
ever not clear to which extent the metabolic recon-
figuration has an active role in maintaining pluripo-
tency, or whether changes in energy metabolism are
causative in driving differentiation. Evidence for an
active role of the PPP in supporting cell proliferation
has however been found by studying the metabolism of
cancer cells.
(1) The role of the PPP in deregulated cell
proliferation and the pathogenesis of cancer: the
Warburg effect
Rising attention has recently been paid to deregulated
cell proliferation when it has been noticed that malig-
nant transformation and metabolic reprogramming
may be intimately intertwined. Despite a vast amount of
research, cancer still represents the second most com-
mon cause of death in the world, beaten to the top only
by cardiovascular diseases.While the last decade has sub-
stantially changed the way cancer therapy is performed,
the majority of newly approved molecular-targeted
drugs (e.g. antibodies against growth factors or their
receptors, tyrosine kinase inhibitors and other small
molecules) failed to result in significant and long-lasting
improvement of therapy efficacy (Fojo & Parkinson,
2010). This is partially explained by the hallmark
genomic instability of malignant cells that results in
an impressive propensity to adapt to and, ultimately,
resist inactivation of ‘cancer-specific’ signalling path-
ways (Bock & Lengauer, 2008; Gillies, Verduzco &
Gatenby, 2012). Inhibition of processes that are abso-
lutely essential and non-redundant for tumour cell pro-
liferation is a promising strategy to improve cancer ther-
apy. Tumour-specificmetabolism clearly represents such
a process. Despite being recognized nearly a century
ago, the fundamental importance of metabolic dereg-
ulation for cancer pathogenesis has escaped the appre-
ciation of most cancer researchers for decades. It was
not until the post-genome era that metabolic repro-
gramming was widely accepted as an emerging hall-
mark of cancer (Hanahan & Weinberg, 2000; Hana-
han & Weinberg, 2011). Recently however, characteri-
zation of cancer metabolism has become the focus of
a rapidly growing research community, taking advan-
tage of the improved analytical and increasingly also
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computational methodology to identify fascinating and
unexpected interactions (Weinberg, 2014). Observed
changes in metabolism are in no way ‘trivial’, indeed
can be quite specific dependent on both the respon-
sible genetic lesion and tumour tissue type (Yuneva
et al., 2012). While the majority of published work anal-
ysed the role of glycolysis, glutaminolysis and mito-
chondrial activity, the importance of the PPP for malig-
nant transformation remained elusive for quite some
time.
Otto Warburg was not only able to identify some of
the first enzymes and co-enzymes of central metabolism,
but at the same time, was one of the first research
pioneers that recognized the importance of altered
metabolism for tumour growth. He and his co-workers
discovered an increase in glucose uptake and lactate
production in concert with a decrease in oxygen uptake
(known as the ‘Warburg effect’), reviewed in (Warburg,
1956). Intriguingly, the elevation in glycolytic flux also
occurred under sufficient oxygen supply (aerobic gly-
colysis). Based on these results, Warburg concluded that
cancer cells must suffer from defects in their respira-
tory machinery. Today, we know that although many
cancers show reduced activity of oxidative phosphory-
lation (OXPHOS; (Ferreira, 2010; Cairns et al., 2011)),
most cancers [with important exceptions, oncocytoma
for instance (Mayr et al., 2008)], possess a fully func-
tional respiratory chain and are therefore biochemically
fully capable of using the respiratory chain for ATP
production.
But why are cancer cells then not fully exploiting
this efficient ATP-producing machinery? A cutback in
OXPHOS seems counterintuitive since rapid prolifera-
tion demands large amounts of energy. This observation
implies that other factors than ATP production are
more limiting for the cancer cell. Recent observations
indicate that a balanced redox state, achieved in part
by increased PPP activity, is essential for tumourigenesis
(Anastasiou et al., 2011; Grüning & Ralser, 2011; Tosato
et al., 2012). A more disputed theory concerns the
cross-feeding of cancer cells through lactate, termed
the ‘Reverse Warburg effect’ (Pavlides et al., 2009).
Although this theory has attractive components, it fails
to explain some aspects of the effect; for instance it
does not explain why other organisms, like yeast cells,
also show Warburg-like metabolic reconfigurations
despite not sharing lactate. Importantly, however, all
these studies indicate that the often heard hand-waving
explanation ‘Respiration is reduced in cancer cells
to save carbon equivalents for biosynthesis’ is to be
questioned as a cause for the Warburg effect: First, res-
piratory activity does not compete with aerobic glycolysis
for carbons, as aerobic glycolysis is followed by lactate
excretion instead of pyruvate decarboxylation. Second,
also the PPP contains a CO2-producing reaction. Thus,
Warburg like cells have a negative carbon balance.
Oxidative stress is a major cause of damage for macro-
molecules and can eventually lead to cell death. On the
other hand, a certain amount of oxidizing equivalents
are certainly necessary for cell physiology, and thus, only
situations with constantly or periodically elevated ROS
levels can be considered as a risk factor for tumourigene-
sis. ROS-inducedDNAdamage can lead to cancerogenic
mutations and genomic instability, and ROS also trigger
inflammatory pathways and have a stabilizing effect
on HIF-1; a transcription factor highly expressed in
cancer cells (Gao et al., 2007; Perera & Bardeesy, 2011;
Wu & Le, 2013). Therefore, the pool of intracellular
ROS must be kept balanced and below a toxic thresh-
old – a drastic shift towards oxidation would cause
tumour cell death (Gao et al., 2007; Perera & Bardeesy,
2011). Thus, dynamic tuning of the metabolic net-
work as well as the antioxidant systems, involving
glycolytic metabolite accumulation and PPP activation,
is of fundamental importance to keep the produc-
tion of cellular building blocks, energy and reducing
equivalents in check. Vice versa however, pro-oxidant
therapies could prove helpful in inhibiting tumour cell
proliferation.
(2) Evidence for enhanced PPP activity in cancer cells
Gene and protein expression analyses together with
immunohistochemistry are widely applied as surrogate
methods to assess the role of specific factors for can-
cer pathogenesis. However, while these methods are
certainly useful and have helped to identify numerous
molecules important for cancer biology, a valid and
detailed characterization of metabolic pathways can-
not be achieved by them. Metabolic pathways appear
mostly regulated by post-translational mechanisms
(Daran-Lapujade et al., 2004; Buescher et al., 2012;
Kochanowski, Sauer & Chubukov, 2013). In addition,
flux of the PPP is dependent on the level of co-factors
(NADP+ for the oxidative PPP), substrate availability
(non-oxidative PPP), and the flux through glycolytic
enzymes. Hence, information about the abundance of
mRNA and also protein levels is limited to pinpoint
accurately changes in PPP activity and their potential
causal importance for cancer biology, so it is required
to determine these values in concert with flux and/or
metabolite concentrations. Due to the difficulty in
applying these techniques in heterogeneous tumours, it
is hence not surprising that published literature is rather
scant. Fortunately, G6PDH is an informative exception
as its enzyme activity in tumours is well studied and was
increased in various human cancer types when com-
pared to the respective benign control tissue, e.g. cervix,
uteri, prostate and breast (Pedersen, 1975; Zampella,
Bradley & Pretlow, 1982; Bezwoda et al., 1985). To the
best of our knowledge, there is less information available
about tumour-specific activities of the non-oxidative
PPP, especially for its key enzymes TAL and TKL.
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Assessment of enzyme activity however points towards
modified PPP flux in cancer. Stable isotope resolved
metabolomics (SIRM), indicates enhanced PPP activ-
ity in the human breast cancer cell line MCF7 when
compared to non-transformed mammary epithelial
cells (Meadows et al., 2008). Similar results have been
obtained in renal cell carcinoma where altered activity
of the PPP has been identified as a keymetabolic feature
of the cancer state (Catchpole et al., 2011). In addition,
PPP adaptation could be crucial for cancer cells that
use glucose alternatives, such as fructose, for their car-
bohydrate needs. There is evidence that in pancreatic
cancer cells, fructose is preferentially metabolized via
the non-oxidative PPP supporting tumour growth (Liu
et al., 2010). In this context, a homologue of TKL,
TKL-like protein (TKTL1) is detected in tumour tis-
sue and its expression level has been correlated with
the progression of cancer (Diaz-Moralli et al., 2011;
Kayser et al., 2011). However, due to the difficulty in
detecting TKTL1 enzymatic activity it is currently unde-
cided whether TKTL1 participates in the PPP or not
(Meshalkina et al., 2013).
As an alternative to the classical biochemical
approaches, functional imaging is becoming increas-
ingly sophisticated and has shown promise as another
more direct method to assess metabolic changes in vivo.
A recent study used intravenous infusion of [1,2-13C2]
glucose, followed by 13C NMR analysis of the micro-
dissected tumour mass and non tumour-bearing sur-
rounding brain, to assess PPP flux relative to glycolytic
flux. The malignant tissue in this study did not show
enhanced PPP flux relative to glycolysis, when com-
pared with the surrounding benign brain tissue
(Marin-Valencia et al., 2012a; Marin-Valencia et al.,
2012b), and it was suggested that damage to the sur-
rounding brain was confounding the measurements.
While the latter two studies demonstrate the potential of
measurements for the PPP flux, it is clear that additional
data are needed from a broad spectrum of tumours
for a more comprehensive picture of PPP activity in
cancer.
New opportunities arise from the use of hyperpo-
larized NMR tracers, as these allow non-invasive and
real-time assessment of metabolic flux in vivo. The
technique has recently been translated to the clinic
with a study in prostate cancer (Nelson et al., 2013).
Intriguingly, in studies on E. coli, yeast and cancer cells,
in vitro signals from glycolytic intermediates have been
detected, such as dihydroxyacetone phosphate, and also
a signal that has been assigned to 6-phosphogluconate,
offering the potential for in vivo measurements of PPP
flux as well. Such measurements have recently been
reported for tumors in vivo, where hyperpolarized
[U-2H, U-13C] glucose and the lactate formed from it
were imaged and the resonance previously assigned
to 6-phosphogluconate was observed (Rodrigues et al.,
2014).
(3) Enzymatic switches enable metabolic adaptation of
cancer cells
Different enzymatic switches could be involved in
triggering and modulating metabolic reprogramming
towards increased PPP flux. Proliferating mammalian
cells have increased levels of glycolytic enzymes, one of
these is represented by PK isozymes M1/M2 (PKM1/2)
(Bock & Lengauer, 2008; Christofk et al., 2008; Hitosugi
et al., 2009; Bluemlein et al., 2011). PK catalyses the
‘final’ step in glycolysis and converts PEP into pyruvate;
a reaction which yields ATP, and is thus required for
the net gain in glycolytic energy production (Fraenkel,
1986).
Most human tissues are dominated by the expres-
sion of one of two mutually exclusive spliceforms of
the PKM gene: PKM1 and PKM2 (Mazurek et al., 2005;
Bluemlein et al., 2011). In most human tissues whether
healthy or cancerous, (bladder, liver, colon, lung, kid-
ney, thyroid, fibroblasts, epithelial cells), but not in
muscle and potentially neurons, PKM2 is the domi-
nantly expressed isoform over PKM1 (Bluemlein et al.,
2011). At least liver and red blood cells express an
additional PK isoform, known as PKLR (Zanella &
Bianchi, 2000).
Among PKM-expressing tissues, the total PKM expres-
sion level and the distribution between the two isoforms
varies significantly, and ranges from 55% PKM2 over
PKM1 of total PKM in (muscle-rich) bladder tissue,
to up to 96% PKM2 of total PKM in colon tissue.
At the same time, in absolute values, the PKM con-
tent ranged from ∼10 fmol/μg total protein in thyroid
to 300 fmol/μg total protein in colorectal carcinoma
(Bluemlein et al., 2011). Hence, the expression level of
the PKM gene appears to be an important determinant
of total pyruvate kinase activity and is highly dependent
on the tissue. In many cancer cells PKM2 expression
is increased when compared to tissue-matched con-
trols (Ashrafian et al., 2010; Bluemlein et al., 2011;
Zhou et al., 2012). Despite the total protein amount
being up-regulated, overall PK activity however does
not increase accordingly, or it is inhibited, suggest-
ing that the specific PKM activity is lowered in the
tumour cells (Hitosugi et al., 2009; Vander Heiden
et al., 2010). This modulation of PK activity creates
the opportunity to switch between high glycolytic
flux, or induce a metabolic reconfiguration towards
OXPHOS and an activated PPP. In contrast to PKM1
that is a tetramer with high constitutive activity (Ima-
mura & Tanaka, 1972; Wu & Le, 2013), PKM2 can be
flexibly tuned and allosterically modulated in activ-
ity and switches between monomeric, dimeric and
tetrameric states (Morgan et al., 2013). Allosteric acti-
vation of PKM2 can be achieved by interaction with
fructose 1,6-bisphosphate, succinylaminoimidazolecar-
boxamide ribose 5′-phosphate (SAICAR) and serine
(Chaneton et al., 2012; Keller, Tan & Lee, 2012). In
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addition, post-translational modifications can modu-
late PKM2 activity. For example, phosphorylation at
tyrosine 105 prevents the formation of the more active
tetrameric form of PKM2 (Hitosugi et al., 2009), and
P300/CBP-associated factor (PCAF)-mediated acetyla-
tion on lysine 305 reduces activity (Wang et al., 2010).
During high ROS levels, lower PK activity could be
essential to maintain cell survival. Similarly to respiring
yeast (section III), cancer cells accumulate PEP because
of reduced PK activity (Anastasiou et al., 2011; Grüning
et al., 2011). Oxidation of PKM2 at cysteine 358 can
decrease its activity and redirect glycolytic intermedi-
ates towards the PPP for the production of NADPH.
Disruption of this mechanism can exacerbate oxidative
stress and subsequently decrease proliferation in cancer
cells (Anastasiou et al., 2011).
What does link decreased PK activity and increased
cellular oxidative capacity? The mechanism seems to
depend on the glycolytic block and PEP accumulation.
PEP interferes with other glycolytic reactions, such as
phosphoglycerate mutase, glucokinase, GPI, PFK, FBA
and TPI (Ogawa et al., 2007; Fenton & Reinhart, 2009;
Grüning et al., 2011; Grüning et al., 2014). The latter
can directly lead to increased PPP activity and stress
protection. Despite in vitro kinetics indicating a low flux
control coefficient of TPI (Knowles & John, 1977), in
vivo experiments detect increased PPP activity when TPI
activity is only slightly compromised (Ralser et al., 2007).
TPI inhibition is sufficient to cause a block in upper
glycolysis and an increase in PPP metabolites (Grüning
et al., 2011; Grüning et al., 2014). This redirection of
metabolites by the PK-PEP-TPI feedback loop enables
cells to adapt to a higher level of ROS and protect from
oxidative damage (Ralser et al., 2007; Grüning et al.,
2014). TPI thus might represent a key enzymatic switch
for metabolic reprogramming. Although low PK and
TPI activity limit the ATP yield from energy metabolism,
the cell’s redox balance is maintained which could be
more important for cancer survival (Cairns et al., 2011;
Grüning & Ralser, 2011).
(4) Interaction of the PPP with oncogenic pathways
(a) p53
The transcription factor p53 represents a tumour sup-
pressor with well-established functions on genomic
integrity, apoptosis and cell cycle control (Vazquez
et al., 2008). p53 is the most commonly mutated gene
in human cancers and its loss constitutes a pivotal
mechanism of therapy failure (Bensaad et al., 2006;
Rohwer et al., 2010). It became evident in recent years
that p53, in addition to the functions outlined above,
exerts control over metabolic pathways. The p53 target
gene TIGAR was shown to dampen glycolysis by low-
ering the level of fructose 2,6-bisphosphate which is a
powerful allosteric activator of PFK1. As a result the
glycolytic intermediates can be diverted to the oxida-
tive or non-oxidative branch of the PPP (Fig. 6). This
leads to decreased cellular levels of ROS due to the
action of NADPH, ultimately resulting in enhanced cell
survival and growth (Bensaad et al., 2006). In highly
proliferative tissues such as the intestine, a lack of
TIGAR in vivo leads to decreased regeneration after
acute stresses such as ulcerative colitis and irradia-
tion, indicating an important role of TIGAR in pro-
liferation (Cheung et al., 2013). Consistently, overex-
pression of TIGAR has been observed in a number of
tumour types, and also in invasive cancer cells com-
pared to normal tissues (Wanka, Steinbach & Rieger,
2012; Won et al., 2012; Cheung et al., 2013). In an in
vivo model of intestinal adenoma where adenomatous
polyposis coli (APC) is deleted in LGR5+ intestinal
stem cells, TIGAR deficiency decreases tumour burden
and average tumour size, which results in increased
disease-free survival in these mice. Tumour intesti-
nal crypts isolated from these mice showed that the
in vitro growth of the TIGAR-deficient tissues can be
rescued by the addition of antioxidants and nucleo-
sides, again indicating an important role of TIGAR
in increasing PPP during proliferation. While the role
of TIGAR in promoting tumour growth seems to be
counterintuitive to p53 as a tumour suppressor, TIGAR
expression is uncoupled from p53 expression in vari-
ous cell lines (Cheung et al., 2013). Hence, it is possible
that a p53 target protein such as TIGAR can become
oncogenic when it is not properly regulated by p53.
Recently, it has been shown that TIGAR predominantly
functions as phosphoglycolate-independent 2,3-bisphos
phoglycerate phosphatase (Gerin et al., 2014). Another
interpretation is thus that p53 could stimulate the
non-oxidative PPP via TIGAR by directly targeting lower
glycolysis. In contrast to this activity of a p53-target gene,
p53 itself can inhibit G6PDH and regulate its activity;
this results in reduced PPP activity and a redirection
of the central carbon flux towards increased glycolytic
activity (Jiang et al., 2011). As a result, p53-deficient cells
display enhanced lipid synthesis as well as reduced sen-
sitivity towards oxidative stress-induced cell death as a
functional consequence of higher oxidative PPP activity
(Jiang et al., 2011). Taken together, p53 seems to influ-
ence the PPP antithetically, both as an inhibitor (via
direct influence on G6PDH) and as an activator (via
TIGAR). These opposing functions of p53 may reflect
the different roles of p53 depending on the severity of
the damage to the cell. During transient andmild stress,
p53 may act as a pro-survival mediator for repair and
regeneration. However, if the damage is too high and
persistent, p53 may switch off the pro-survival mode for
the proper elimination of irreversibly damaged cells. In
some cases, as a result of p53 activity, the homeosta-
sis and integrity of the tissue as a whole is preserved.
Interestingly, p73 (a p53 relative) was shown to enhance
the PPP by activating the expression of G6PDH under
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conditions where p73 showed tumour-promoting activ-
ities (Du et al., 2013). While illustrating the complexity
of function of the p53 family of proteins, these studies
support the general notion that flux through the PPP
supports cancer cell growth.
(b) ATM kinase
PPP activity can be also stimulated by the kinase
ataxia telangiectasia mutated (ATM). ATM is a serine/
threonine kinase which is activated by DNA double-
strand breaks and phosphorylates enzymes which are
required for DNA checkpoint control and cell cycle
arrest (Furgason & Bahassi, 2013). It phosphorylates
the heat shock protein 27 (HSP27) which forms a com-
plex with the first enzyme of the oxidative branch of
the PPP: G6PDH. This interaction activates G6PDH
and increases its activity supporting elevated PPP flux
(Cosentino et al., 2011) (Fig. 6). Therefore, by connect-
ing genome stability and cell cycle control to PPP activa-
tion andmetabolic adaptation, ATM represents another
crucial hub for cellular homoeostasis during tumouri-
genesis (Cosentino et al., 2011; Krüger & Ralser, 2011;
Ditch & Paull, 2012).
(c) K-ras
The proto-oncogene K-ras is found activated in a num-
ber of human cancers, in particular adenocarcinomas
of the pancreas, lung and colon (Downward, 2003).
The observation that K-ras-transfected murine fibrob-
lasts display enhanced resistance against oxidative
stress via NADPH-mediated glutathione recycling first
pointed towards a potential importance of the PPP
for K-ras-induced transformation (Recktenwald et al.,
2008). Subsequently, it was found that oxidative stress is
induced upon matrix detachment of cells and that resis-
tance against detachment-induced cell death (anoikis)
largely depends on antioxidant capacity (Schafer
et al., 2009). Intriguingly, anoikis resistance, which
represents a central hallmark of malignant cells and a
fundamental prerequisite for metastatic dissemination,
in K-ras-driven human colon and mammary cancer
cells, depends on functional integrity of the PPP (Wein-
berg et al., 2010). While these results point towards
a functional importance of PPP-mediated antioxi-
dant capacity for K-ras-driven tumourigenesis, ROS
generation has shown to be essential for the full onco-
genic potential of K-ras (Weinberg et al., 2010). These
apparently contradictory results clearly need further
experimental clarification before a clear-cut picture
of the interplay between K-ras and the PPP during
malignant transformation can be proposed (Fig. 6).
(d) HIF-1
The hypoxia-inducible transcription factor HIF-1 is
found overexpressed in the majority of human cancers
and regulates pivotal pro-tumourigenic features such
as angiogenesis, glucose uptake and glycolysis as well
as resistance towards apoptosis and anoikis (Rohwer
et al., 2013). Research on the role of HIF-1 for glu-
cose metabolism was long dominated by HIF-1’s robust
effect on glucose transport and glycolysis while experi-
mental data supporting a role for HIF-1 in the control
of cancer-associated PPP activity is intriguingly meagre.
Analyses of the importance of oxidative stress during
the pathogenesis of Alzheimer’s disease first reported
a functional role of HIF-1 for enhanced PPP activity
(Soucek et al., 2003) (Fig. 6). Later, experimental evi-
dence supported a critical role of HIF-1-mediated PPP
activation in cellular antioxidant capacity of neurob-
lastoma cells (Guo et al., 2009). The most compelling
experimental evidence in this regard was published by
Craig Thompson’s group: analysing chronic myeloid
leukemia (CML) cells, they reported robust activa-
tion of HIF-1 in cells exhibiting resistance towards the
tyrosine-kinase-inhibiting therapeutic imatinib (Zhao
et al., 2010). This HIF-1 activation was associated with
reduced flux through the oxidative branch of the PPP
while the glycolytic rate was significantly enhanced.
On the other hand, the non-oxidative PPP branch was
found activated in a TKL-dependent manner in cells
with stabilized HIF-1, thereby supplying ribose synthe-
sis essential for cellular proliferation (Zhao et al., 2010).
Chemical inhibition of TKL resulted in enhanced ima-
tinib sensitivity in vitro and in vivo against CML, pointing
towards a functional role of HIF-1-driven non-oxidative
PPP in mediating resistance against targeted therapies.
These results are especially intriguing as imatinib rep-
resents the only targeted therapeutic that was able
to result in undisputed and long-lasting clinical ben-
efit of patients with cancer. This work supports the
notion of HIF-1 as a pivotal mediator of therapy failure
and points towards HIF-1-dependent control of cellu-
lar metabolism as an important molecular mechanism
(Rohwer & Cramer, 2011).
(e) PI3K-Akt/mTORC1
Aberrant activation of the signalling cascade compris-
ing phosphatidyl inositol kinase (PI3K), protein kinase
B (PKB/Akt) and the mammalian target of rapamycin
complex 1 (mTORC1) is commonly observed in
the majority of human cancers (Laplante & Saba-
tini, 2012). It became evident in recent years that
mTORC1 exerts pro-tumourigenic activity not only
via its well-established roles in protein synthesis and
autophagy, but also via elaborate control over cellu-
lar metabolism. A genomic approach unravelled that
mTORC1 induces a variety of genes that encode for
specific metabolic pathways, e.g. glycolysis, lipid and
sterol biosynthesis as well as both branches of the
PPP (Düvel et al., 2010). Despite these encourag-
ing results, the functional importance of the PPP for
mTORC1-driven cancers as well as the molecular nature
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Fig. 6. The pentose phosphate pathway (PPP) is associated with several cancer- and cell-proliferation-related signalling
cascades. The p53 pathway can stimulate the PPP by inhibiting phosphofructokinase 1 (PFK1) through TP53-induced
glycolysis and apoptosis regulator (TIGAR), and by inhibiting glucose 6-phosphate dehydrogenase (G6PDH). This enzyme
is also targeted by the ataxia telangiectasia mutated (ATM) kinase, which increases G6PDH activity by phosphorylating
heat shock protein 27 (HSP27), and an NAD-dependent deacetylase (SirT2), which acts on this enzyme directly by
de-acetylation. All three mechanisms activate the oxidative branch of the PPP, which is also controlled by the mammalian
target of rapamycin complex 1 (mTOR) pathway. Cancer signallingmechanisms operate alongside allosteric andmetabolic
regulation. For instance, reduced pyruvate kinase PKM2 activity leading to triosephosphate isomerase (TPI) inhibition
increases the carbohydrate flux towards the PPP, achieving a metabolic self-regulation that counteracts oxidative stress.
The activity of the PPP itself has an influence on cancer signalling pathways. The antioxidant capacity of the PPPmodulates
proto-oncogene k-ras-driven tumourigenesis; concurrently, reactive oxygen species (ROS) can potentiate the oncogenic
activity of k-ras (the two opposing regulations are highlighted). The PPP has also been associated with drug resistance
and hypoxia. Depending on the sensitivity to imatinib, chronic myeloid leukaemia (CML) cells can either exhibit reduced
(sensitive cells) or increased (resistant cells) transketolase (TKL) activity after hypoxia-inducible transcription factor 1
(HIF-1) activation. F 2,6-BP, fructose 2,6-biphosphatase; P13K (Phosphatidylinositol-3-kinase), Akt (protein kinase B);
PEP, phosphoenolpyruvate.
of mTORC1 activation of PPP genes remains elusive.
The antioxidant capacity needed to promote survival of
tumour cells after detachment from the extracellular
matrix depends on PI3K-Akt-induced activation of the
oxidative PPP (Schafer et al., 2009) (Fig. 6).
(f ) Alternative pathways of PPP activation in cancer
The notion that increased PPP activity is beneficial
for cancer cells is also supported by other studies that
propose alternative mechanisms of PPP activation
in cancer cells. For example, phosphofructokinase
1 (PFK1) is inhibited in cancer cells through gly-
cosylation, drives PPP flux and supports cancer cell
growth (Yi et al., 2012). Vice versa, the depletion of
6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase
4 (PFKFB4) inhibits cancer cell growth by lowering
flux through the PPP (Ros et al., 2012). Moreover, a
study addressing the plant stilbenoid resveratrol indi-
cates that its suppressive function on human colon
cancer cell proliferation is attributable to PPP targeting
and talin-focal adhesion kinase (talin-FAK) signalling
pathways as well (Vanamala et al., 2011).
(5) Conclusions about the role of the PPP in cancer
metabolism
While the prognosis of certain types of cancers (e.g.
breast and colon cancer) has improved in recent years,
we are still eagerly awaiting successful clinical transla-
tion of the billions of funding and an uncountable num-
ber of working hours that have been invested in can-
cer research in the last 40+ years. Otis W. Brawley, chief
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medical officer of the American Cancer Society, once
said ‘One cancer cell is smarter than 100 brilliant cancer
scientists’. We still need to unravel the basic principles
that enable malignant transformation, unchecked pro-
liferation, systemic spread and therapy resistance. There
is good reason to believe that understanding cancer
metabolismmight provide an important contribution to
these attempts. The study of the PPP could be central, as
the pathway is at the crossroads of both oncogenic sig-
nalling and biosynthetic pathways. In this respect, first
results are promising: in a recent study, PPP activity was
predictive for the efficacy of cancer therapeutics (Folger
et al., 2011).
IX. THE ROLE OF THE PPP IN BRAIN ENERGY
METABOLISM
The brain energy demands to maintain its physiologi-
cal signalling activities are extremely high. Although it
represents only 2% of the total body mass, the adult
human brain is believed to consume about 20% of oxy-
gen respired at rest (Silver & Erecin´ska, 1998; Bélanger,
Allaman &Magistretti, 2011). A developing brain might
have even greater requirements, as estimates suggest
that an infant’s brain can utilize more than 40% of
basal metabolic rate (Goyal et al., 2014). These large
amounts of energy are needed for the maintenance and
restoration of ionic gradients and for synaptic trans-
mission (Attwell & Laughlin, 2001). The majority of
ATP is generated through OXPHOS, therefore imply-
ing the strict reliance of neuronal activity on mito-
chondria functionality and oxygen supply (Ames, 2000;
Erecinska, Cherian & Silver, 2004). Accordingly, mito-
chondrial impairment has a great impact on neuronal
function and survival (Nicholls & Budd, 2000; Kann &
Kovács, 2007), and it is considered a key pathogenic
player in several neurodegenerative and neurodevel-
opmental disorders (Fiskum, Murphy & Beal, 1999;
Beal, 2005).
Glucose represents the normal obligatory energy
substrate of the brain, and 25% of its daily intake is
assumed to be dedicated to cerebral functions (Cremer,
1982; Bélanger et al., 2011). A steady glucose supply is
necessary since the central nervous system (CNS) is able
to store only a limited amount of glycogen within astro-
cytes (Brown&Ransom, 2007), glial cells outnumbering
neurons in the human brain. Interestingly, quantitative
measurements of whole-brain metabolism showed that
about 10% of consumed glucose is in excess of oxygen
utilization (Fox et al., 1988). Therefore, glycolysis-based
metabolism appears of fundamental importance for
the energetic needs of active neuronal tissue. Stud-
ies of primary cultures of glia and neurons helped
to demonstrate the physiological metabolic compart-
mentalization of the CNS. In particular, astrocytes are
mainly glycolytic and convert glucose into lactate (Itoh
et al., 2003). This lactate can then be transferred to
neurons via the so-called ‘astrocyte–neuron lactate
shuttle’ and eventually employed by the neurons for
OXPHOS-based ATP generation (Pellerin & Mag-
istretti, 1994; Kasischke et al., 2004). This model is
supported by a cell-type-specific expression pattern of
regulatorymembers of carbonmetabolism (Lovatt et al.,
2007). These include glucose transporters (GLUT1 in
astrocytes and GLUT3 in neurons), lactate dehydroge-
nase (LDH1 in astrocytes favouring lactate generation
and LDH5 in neurons supporting pyruvate formation
from lactate), and lactate transporter (monocarboxy-
late transporter MCT1/4 in astrocytes promoting
lactate release and MCT2 in neurons promoting lac-
tate uptake) (Fig. 7) (Bittar et al., 1996; Ames, 2000;
Bélanger et al., 2011).
An interesting consequence of the metabolic cou-
pling between astrocytes and neurons is the peculiar
neuronal dependence on PPP activity. Indeed, lac-
tate utilization as an oxidative substrate for energy
production in neurons may represent a mechanism
for circumventing glycolysis and thus sparing neuronal
glucose for the PPP (Bolaños, Almeida & Moncada,
2010). In particular, a fundamental regulatory role has
been proposed for the enzyme 6-phosphofructose-2-
kinase/fructose-2,6-biphosphatase-3 (PFKFB3), which
generates fructose 2,6-bisphosphate (F2,6BP), a
potent activator of the rate-limiting glycolytic enzyme
phosphofructokinase-1 (PFK1) (Hue & Rider, 1987).
Due to constant proteasomal degradation, PFKFB3 is
absent in neurons and cannot be activated upon inhibi-
tion of mitochondrial respiration (Almeida et al., 2001;
Herrero-Mendez et al., 2009). On the contrary, PFKFB3
is expressed in astrocytes was upregulated upon mito-
chondrial impairment in order to increase the glycolytic
rate (Herrero-Mendez et al., 2009). Therefore, the high
neuronal sensitivity to mitochondrial dysfunction may
be due to their inability to sustain elevated glycolysis
because of their dependence on PPP-based utilization
of glucose. A similar mechanism may also be present in
cancer cells, where PFKFB3 has been reported to dis-
play reduced methylation and enhanced degradation
in the proteasome, resulting in the shunt of glucose
away from glycolysis and towards the PPP (Yamamoto
et al., 2014).
The main reason underlying neuronal dependence
on glucose metabolism via the PPP may be the main-
tenance of redox homeostasis (Fernandez-Fernandez,
Almeida & Bolaños, 2012). Indeed, to counteract the
increase in ROS, common by-products of OXPHOS,
neuronal cells would need an antioxidant defence
mechanism constantly in place. To this end, the produc-
tion of NADPH within the oxidative branch of the PPP
is critical, as it represents the main electron donor for
the generation of reduced glutathione (GSH) through
the enzyme glutathione reductase (GR). GSH is in
turn employed as electron donor for the reduction of
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Fig. 7. The pentose phosphate pathway (PPP) in neuronal energy metabolism. Schematic representation of glucose
metabolism in neurons (left) and astrocytes (right). Metabolic regulators differentially expressed between neurons and
astrocytes are highlighted. Summarized is evidence that astrocytes ferment glucose to lactate which is secreted aside GSH
into the intracellular space. Neurons then uptake lactate and GSH; lactate is then converted to pyruvate and enters the
tricarboxylic acid cycle to generate ATP over the respiratory chain. Abbreviations: as in Table 1; GSH, glutathione; GSSG,
glutathione disulfide; GLUT, glucose transporters; GR, glutathione reductase; GPx, glutathione peroxidase; LDH, lactate
dehydrogenase; MCT, monocarboxylate transporter.
detrimental peroxides (ROOH) by glutathione perox-
idase (GPx) (Dringen, 2000). Interestingly, although
this process may be essential in neurons, it has been
shown that astrocytes are better equipped to stimulate
the PPP, and the consequent NADPH generation, in
response to oxidative stress (Ben-Yoseph, Boxer & Ross,
1996a; García-Nogales, Almeida & Bolaños, 2003). Neu-
rons are also less capable than astrocytes in utilizing
extracellular cysteine, used as precursor of GSH, and
thus rely on the uptake of GSH that has been pro-
duced and released by the astrocytes (Dringen, 2000).
These data emphasize the susceptibility of neuronal
cells to redox imbalance and their crucial necessity
for PPP-based glucose metabolism (Ben-Yoseph, Boxer
& Ross, 1996b). In accordance, brain PPP activity has
been found induced upon experimental brain injury
in mice and after traumatic brain injury in humans
(Bartnik et al., 2005; Dusick et al., 2007). Furthermore,
malfunction of the PPP is associated with the appear-
ance of neurological symptoms (Herken, Lange &
Kolbe, 1969).
Recent findings suggest a second reason behind the
importance of the PPP in brain metabolism. A meta-
analysis of glucose and oxygen consumption through-
out the human lifespan and among different brain
regions suggests that non-oxidative glucose utilization
may be important during development to support
synaptic remodelling (Vaishnavi et al., 2010; Goyal et al.,
2014). This may imply that the nucleotide biosynthe-
sis derived by PPP activity might be crucial in neurons
for synaptic plasticity (Magistretti, 2014). Indeed, the
PPP/glycolysis ratio has been found to be higher in
neonatal brain compared to adult brain (Baquer et al.,
1977; Morken et al., 2014).
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The current model of neuron/astrocyte bioenerget-
ics has been questioned by some groups (Dienel, 2012),
as it has been shown that during network activation
neurons may be as capable as astrocytes at employ-
ing glucose as an energy substrate (Ivanov et al., 2014).
Accordingly, glycolysis-generated ATP appears of fun-
damental importance for vesicle motility (Zala et al.,
2013). Therefore, as mitochondria may be unevenly dis-
tributed in the neuronal cells, the glycolytic machinery
may provide the constant energy needed for fast axonal
transport (Zala et al., 2013).
Overall, our understanding of human brain energy
metabolism is still limited. Perhaps, recent advances in
stem cells and neuronal differentiation (Jakel, Schnei-
der & Svendsen, 2004; Sandoe & Eggan, 2013) might
be helpful in providing human CNS cells for the study
of neuroenergetics at the cellular and molecular level.
This might potentially clarify the role of the PPP in the
CNS and the interplay between different human brain
cell types in the basal state and under conditions stimu-
lating remodelling of energy flux.
X. CONCLUSIONS
The PPP is a central component of metabolism in
the majority of single- and multicellular organisms.
Despite the pathway is central and evolutionary ancient,
it possesses a high level of flexibility, which renders it
an attractive target for biotechnology and medicine.
In summary
(1) The main biochemical function of the PPP is
the biosynthesis of nucleic-acid and amino-acid sugar
phosphate precursors.
(2) This function of the PPP is bound to the provision
of biochemical reducing equivalents in form of NADPH,
which renders the PPP an important player in maintain-
ing redox homeostasis.
(3) The PPP is highly flexible, dynamic, and is adapt-
ing to varying nutrient supply and stress conditions. This
coordinates these functions and is required meet cellu-
lar metabolic demands in the constantly changing envi-
ronment.
(4) The PPP is important for biotechnology, as its
flexibility can be exploited to tune NADPH production,
and for medical research, as the PPP activity is altered by
bacterial and eukaryotic parasites during the infection
process, when stem cells differentiate, when cancer cells
maintain redox homeostasis, and in neurons to sustain
energy metabolism.
(5) Unveiling the complex regulation of the PPP,
which despite 80 years of detailed basic and med-
ical research is still not fully understood, appears
hence essential for addressing metabolic adaptation
and its consequences on cellular and organismic
physiology.
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